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ABSTRACT
CO-SENSITIZATION OF DOPAMINE AND SEROTONIN RECEPTORS OCCURS 
IN THE ABSENCE OF A CHANGE IN THE DOPAMINE D, RECEPTOR 
COMPLEX AFTER A NEONATAL 6-OHDA LESION
by 
Li Gong
To test whether SKF 38393 could ontogenetically 
sensitize dopamine (DA) D, receptors and whether this 
sensitization would be associated with biochemical changes, 
intact and neonatal 6-hydroxydopamine (6-OHDA)-lesioned rats 
(200 pq i.c.v.) were treated daily from birth with SKF 38393 
(3.0 mg/kg i.p. x 28 days) or its vehicle. In DA D, 
neonatally sensitized 6-OHDA rats, enhanced locomotor 
responses were observed with the first SKF 38393 challenge 
dose (3.0 mg/kg i.p.) at 6 weeks. This response increased 
further with weekly SKF 38393 treatments. Enhanced 
stereotyped behaviors were seen in both lesioned and 
sensitized rats at 8 weeks. There was no change in the 
percentage of high affinity D, sites in these groups of 
rats. Striatal mRNA levels for D, receptors were reduced in 
the lesioned rats, but restored to control level after 
treatments with SKF 38393 in adulthood. Basal, DA-, NaF- 
and forskolin-stimulated adenylate cyclase activities were 
similar among treatment groups. Striatal DA content was 
reduced (>99%), whereas serotonin (5-HT) content was 
elevated (>50%) in the 6-OHDA groups. To study possible 
interaction between DA and 5-HT systems, the effects of a 
series of 5-HT agents on the induction of oral activity were 
determined. The 5-HTlc receptor agonist, m- 
chlorophenylpiperazine (m-CPP), produced a marked increase 
in oral activity in 6-OHDA-lesioned rats. The respective 5- 
HT,A and 5-HT,B agonists, 8-OH-DPAT and CGS-12066B did not 
increase oral activity. The m-CPP-induced oral response in 
the lesioned rats was attenuated by mianserin, a 5-HT,c 
antagonist, but not by ketanserin or MDL-72222, 5-HT2 and 5- 
HTj antagonists, respectively. Although the supersensitized 
oral response of lesioned rats to m-CPP was not attenuated 
by SCH 23390, the enhanced response of SKF 38393 was 
attenuated by mianserin. Additionally, mRNA levels for 5- 
HT1C receptor were not altered in both intact and lesioned 
rats. These findings demonstrate that ontogenetic 
treatments of neonatal 6-OHDA-lesioned rats with a D, 
agonist produce partial sensitization of DA D, receptors in 
adulthood without altered biochemical markers, and that this 
neonatal lesion is associated with both supersensitized DA 
D, and 5-HTlc receptors. Moreover, induction of oral 
activity by DA agonists is mediated via a serotonergic 
system.
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Chapter 1 
Introduction
Anatomical Review of Dopamine system
Dopamine (DA), a veritable newcomer to the field of 
monoamine transmitters in mammalian central nervous system 
(CNS), belongs to a class of compounds termed catecholamines 
(Montagu, 1957). Until the mid-1950s DA was simply 
considered to represent an intermediate precursor in the 
biosynthesis of norepinephrine and epinephrine. Because the 
concentration of DA is almost equal to those of 
norepinephrine in the brain, and because the regional 
distribution of these two catecholamines is markedly 
different, it was proposed that the biological role for DA 
in CNS is independent of its function as a precursor in 
norepinephrine synthesis (Carlsson et al., 1958? 1959).
With the development of histochemical and immunocytochemical 
methods for visualizing catecholamines in brain tissue 
sections (Dahlstrom and Fuxe, 1964? Fuxe et al., 1978), it 
is now convenient to localize dopaminergic pathways under 
several major categories as follows:
l. Nigrostriatal DA system, A group of cell bodies, 
designated the A9 group, are located primarily in 
the substantia nigra pars compacta. These neurons 
project mainly into neostriatum (principally the 
caudate and putamen), globus pallidus and
1
subthalamic nucleus.
2. Hesollmbic DA system. One group of DA-containing 
neurons, known as the A10 group, originates in the 
ventral tegmental area and terminates in the 
nucleus accumbens, olfactory tubercle and nucleus 
interstitialis stria terminalis.
3. Mesocortical DA system. Neuronal cell bodies are 
also located in the ventral tegmental area (A10 
group), but their projections end in the septum, 
prefrental cortex, cingulate, hippocampus and 
amygdala.
4. Mesothalamic DA system. Another group of cell 
bodies originates in the ventral tegmental area (A10 
group) and terminates in the medial and lateral 
habenula.
5. Tuberoinfundibular and tuberohypophyseal DA system.
A system consisting of both short and intermediate- 
length neurons, designated the A12 group, arises 
from the arcuate and periarcuate nucleus and the 
ventral periventricular hypothalamic nucleus, and 
terminates in the median eminence, infundibular 
stalk, intermediate and neural lobes of the 
pituitary.
Ontogeny of Dopamine System
Neuron production in the rat is largely prenatal
(Brasel et al., 1970). The features of the postnatal 
developmental process are mainly related to events involving 
neuronal growth, axonal outgrowth and the synaptic 
formation. The development of dopaminergic fiber systems in 
rats takes place in the first few postnatal weeks. Several 
striatal components including DA-containing nerve endings, 
the neurotransmitter DA and DA receptors show transformed 
patterns during development.
At birth, dopaminergic fibers can be visualized in 
distinct patches' revealed by histofluorescence and 
immunocytochemistry (Moon Edley and Herkenham, 1984; Voorn 
et al., 1988). Soon after birth, denser appearance of DA 
terminals in a * matrix' pattern in the striatum can be 
discerned (Gerfen et al., 1987). By 3-4 weeks after birth, 
the striatal pattern of DA fiber innervation continues to 
mature and appears to reach an adult-like alignment (Moon 
Edley and Herkenham, 1984; Voorn et al., 1988).
similarly, DA content in the developing brain exhibits 
the same picture (Loizou and Salt, 1970). At the first day 
after birth, the striatum contains only about 12% of the 
adult level of DA (Giorgi et al., 1987). The striatal DA 
level increases slowly thereafter, reaching adult levels 7-8 
weeks after birth and remaining constant throughout 
adulthood (Breese and Traylor, 1972; Giorgi et at., 1987; 
Broaddus and Bennett, 1990).
Ontogenetic studies with neonatal rats demonstrated
that a first-week postnatal striatum lacks spontaneous 
neuronal activity (Cheronis et al., 1979; Napier et al.,
1985). Striatal neuronal activity can be recorded from 17 
day old pups. As the variety of striatal cell firing 
patterns increased with age, 28 day old rats have been 
observed to have similar patterns often seen in adult 
striatum (Napier et al., 1985).
The above mentioned findings indicate that 
developmental changes occur in nigrostriatal dopaminergic 
projections and their connections especially during the 
first 8 weeks after birth.
proposed Functions of Dopamine System
Based on anatomical, biochemical, behavioral and 
pharmacological characteristics, there is compelling 
evidence that DA serves as both a neurotransmitter and a 
modulator in the brain. The physiological role of the 
central dopaminergic system has been proposed as follows:
1. Behavioral modulation. A variety of behaviors are 
found to be regulated by the dopaminergic system.
In general, the nigrostriatal pathway may largely 
modulate motor behavior (Ungerstedt and Arbuthnott, 
1970; Ungerstedt, 1971a,b), as evidenced by 
characteristic motor disorder associated with its 
degeneration in Parkinson's disease (Hornykiewicz, 
1966). Numerous studies have suggested that
mesolimbic and mesocortical pathways regulate not 
only motor function, but mainly emotional and reward 
behavior, as well as cortical and subcortical 
functions, i.e. stereotyped behaviors (Creese and 
Iversen, 1973), self-stimulation behavior (Phillips 
and Fibiger, 1973), stimulus control behavior (Ho 
and Huang, 1975) and locomotion (Pijnenburg et al., 
1976). Dysfunction of mesolimbic dopaminergic 
pathway has been hypothesized to underlie the 
etiology of schizophrenia and depression (Stevens, 
1973).
2. Neuroendocrine function. The tuberinfundibular DA 
system regulates secretion of prolactin and 
gonadotropin releasing hormone, and inhibits release 
of somatostatin and thyrotropin releasing hormone.
Dopamine Receptors
Ample evidence has been provided that there are 
multiple receptors for DA in the CNS, on the basis of 
pharmacological, biochemical, anatomical and physiological 
features (Kebabian and Caine, 1979; Creese and Leff, 19S2; 
Creese et al., 1983; Stoof and Kebabian, 1984).
Classically, upon agonist stimulation, DA D, receptors are 
associated with activation of adenylate cyclase (AC)
(Kebabian and Caine, 1979; Seeman, 1980). DA Dj receptors, 
on the other hand, are either unlinked to stimulation of AC,
or have an inhibitory effect on the enzyme (Memo et al., 
1986; Onali et al., 1984; 1985).
characterization and Localization of Dopamine p. Receptors
Pharmacological studies, performed with radioligand 
binding to discriminate between these two receptor 
categories, have aided substantially in characterizing DA 
receptor populations. Dt receptors have been characterized 
by using (JH]-cis**(Z)-flupenthixol (Hyttel, 1978; Murrin, 
1983) and [3H]-cis-(Z)-piflutixol (Hyttel, 1981). However, 
both radioligands produce similar affinities for D( and Dj 
receptors and cause a high degree of nonspecific binding.
SCH 23390 [R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl- 
5-phenyl-lH-3-benzazepine-7-ol] was later introduced as the 
first highly selective D, receptor antagonist and designated 
as the most suitable ligand for D, receptors (Hyttel, 1983; 
Iorio et al., 1983; Billard et al., 1984; Schulz et al., 
1984; Andersen et al., 1985). In vitro, SCH 23390 potently 
blocks DA-stimulated adenylate cyclase (Iorio et al., 1983) 
and selectively displaces [3H]-piflutixol binding from 
striatal slices (Hyttel, 1983). However, in the [JH]- 
spiperone binding assay (a ligand for D2 receptor), SCH 
23390 displays a relatively low affinity at the micromolar 
range and is about 460 times weaker than other neuroleptics 
such as haloperidol. in vivo, this compound is a potent and 
selective antagonist of the D, receptor, with little
affinity toward D2 receptors in the CNS (Andersen and 
Groenvald, 1986; Andersen and Nielsen* 1986).
Regional distribution and density of DA Dt receptors in 
rat brain have been described by using autoradiographic 
studies with [3H] SCH23390. The highest density of D, 
receptors was found in the caudate-putamen, nucleus 
accumbens, olfactory tubercle and the substantia nigra par 
compacta or pars reticulata (Dawson et al., 1986; Savasta et 
al., 1986). High densities was also observed in amygdala, 
nucleus interstitialis stria terminalis, entopeduncular 
nucleus and island of Calleja. Moderate to low numbers of 
Dj sites was found in cerebral cortex, several thalamic, 
hypothalamic and hippocampal areas, the habenula, the 
ventral tegmental area, the cingulate and the cerebellum.
The topographical distribution of D, receptors in the 
striatum was much greater in the ventrolateral and medial 
margin subregion than in the ventromedial and dorsolateral 
sectors, and a rostrocaudal decrease in the densities of D, 
receptors was also noticed (Savasta et al., 1986).
The regional localization of mRNA for Dt receptors has 
been determined by northern blot and by in situ 
hybridization histochemistry. In general, the areas of 
highest expression of D, receptors are the caudate-putamen, 
nucleus accumbens and olfactory tubercle. D, receptor mRNA 
is also observed in the cerebral cortex, limbic system, 
hypothalamus and thalamus (Fremeau et al., 1991; Sibley and
8Monsma, 1992).
Signal Transduction Systems of Dopamine D, Receptors
Striatal DA D, receptors have been shown to mediate the 
DA-stimulated increase of adenylate cyclase (AC) activity 
(Kebabian and Caine, 1979). In membrane preparations, the 
stimulation of AC activity can also be elicited by GTP and 
forskolin, which specifically act on stimulatory guanine 
nucleotide regulatory protein (N.) or catalytic subunit of 
the enzyme, respectively, rather than the receptor site 
(Rodbell, 1980; Seamon et al., 1981). DA, GTP and forskolin 
thus have been widely used as biochemical markers in 
adenylate cyclase assays to determine the functional 
integrity of each subunit in DA Dt receptor complex system, 
and to investigate Dt receptor/effector mechanisms.
There are also growing lines of evidence that 
stimulation of DA receptors leads to changes in 
phosphoinositide metabolism. An early study by Hokin (1970) 
showed variable effects of DA on incorporation of nP into 
phosphatidate and phosphatidylinositol in slices of the 
guinea pig brain. Later, both stimulatory and inhibitory 
effects of DA on phosphoinositide labeling were found 
(Abdel-Latif et al., 1974; Odarjuk et al., 1986). Undie and 
Friedman (1990) demonstrated that the stimulation of DA D( 
receptors enhances inositol phosphate formation in rat 
brain. By injecting mRNA from rat striatum into oocytes of
9Xenopus laevis, Mahan et al. (1990) also showed the 
expression of striatal D, receptors coupled to inositol 
phosphate production.
Dynamics of Dopamine D, Receptors
The binding of antagonists to DA D, receptors show mass 
action characteristics, whereas agonist binding displays two 
separate states of high and low affinity (Hamblin et al., 
1984; Leff et al., 1985). This heterogeneity was 
demonstrated by shallow two-component curves of agonist 
competition for radiolabeled antagonist binding. In the 
presence of guanine nucleotides, the high affinity agonist- 
receptor complex is converted to low affinity agonist 
binding states of the receptors (Hamblin et al., 1984; Leff 
et al., 1985; Hess et al., 1986). These studies have 
proposed a generalized ternary complex model to explain 
these phenomena, which has been modified from the original 
models of Boeynaems and Dumont (1975) and Jacobs and 
Cuatrecasas (1976), and proposed for several other 
monoaminergic receptors (Limbird, 1981).
Qntoaenv of Dopamine D, Receptors
Dopaminergic innervation of the striatum plays an 
important role in regulating the development of neurons 
intrinsic to the striatum (Rosengarten and Friedhoff, 1979). 
There is increasing evidence that the ontogeny of DA
receptors and their mediated responses are dependent upon 
the maturation of their corresponding presynaptic nerve 
terminals. DA Dt receptors are at low levels at birth (9% 
of the adult value) and increase in number thereafter 
(Giorgi et al., 1987; Zeng et al., 1988), attaining a peak 
value at postnatal day 35 (Giorgi et al., 1987). There were 
no alterations in affinity (Kd) of [JH]piflutixol and[3H]SCH 
23390 for D, receptors during development (Zeng et al.,
1988; Gelbard et al., 1989; Broaddus and Bennett, 1990). 
Giorgi et al. (1987) showed that maximum DA-stimulated 
adenylate cyclase (AC) activity in striatum has a 
developmental profile similar to DA Dt receptors, suggesting 
that the postnatal increase in AC activity is attributable 
to the increase in stimulatory receptor density. The 
ontogeny of D, receptors parallels those seen with several 
other markers associated with presynaptic dopaminergic 
terminals in striatum, including DA content, DA uptake 
(Coyle and Campochiaro, 1976), and tyrosine hydroxylase 
activity (Coyle and Axelrod, 1972).
Molecular Biology of Dopamine Receptors
With the molecular characterization of DA receptors 
being facilitated by the cloning of cDNAs and/or genes, two 
subtypes of DA D, receptors and four subtypes of D2 receptors 
have already been identified. The D, receptor of human and 
rats in CNS has been cloned, expressed and characterized
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(Zhou et al., 1990; Dearry et al., 1990), while its subtype, 
termed Djr has recently been identified and cloned as well. 
The Dj receptor bears resemblance to the cloned D, receptor. 
But pharmacologically, the D5 receptor has a 10-fold higher 
affinity for the endogenous agonist, DA (Sunahara et al., 
1991.).
Two forms of the DA D* receptor, D2 short and D2 long, 
were identified by gene cloning and found to be derived from 
alternative splicing of a common gene (Dal Toso et al.,
1989; Giros et al., 1989). A third subtype of the D2 
receptor, termed Dj receptor and characterized by its 
different anatomical distribution and pharmacological 
profile, was isolated by the screening of rat brain cDNA and 
genomic libraries (Sokoloff et al., 1990; Bouthenet et al., 
1991). The fourth subtype of the D2 receptor, the D4 
receptor, has been recently cloned. Its pharmacological 
profile is similar to that of the D2 and Dj receptors. The 
affinity of the D4 receptor for the atypical antipsychotic 
drug, clozapine, however, is an order of magnitude higher 
than for D2 and D3 receptors (Van Tol et al., 1991).
A better understanding of which DA receptor subtype 
mediates particular physiological effects would greatly 
facilitate the development of more specific dopaminergic 
agents and provide insight into the mechanisms of disorders 
thought to be related to the malfunctioning of the DA 
system.
Innervation of Serotonin Flbera to the Striatum
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The existence of serotonin (5-HT) innervation in 
mammalian neostriatum was first shown by regional 
biochemical examination of this monoamine, and by activity 
of its biosynthetic enzyme, tryptophan hydroxylase in the 
dog and cat brain (Bogdanski et al., 1957; Peters et al., 
I960). Fluorescent histochemical and autoradiographic 
investigations further provided evidence of this 5-HT 
innervation in rat striatum (Arluison and Delamanche, 1980; 
van der Kooy and Hattori, 1980; Parent et al., 1981). The 
distributional characteristic of the 5-HT innervation in 
adult rat striatum demonstrated a marked heterogeneous 
pattern (Ternaux et al., 1977; Steinbusch, 1981). The 
neostrlatal 5-HT fiber network has a higher density in 
ventral vs. dorsal parts, and a caudo-rostral decreasing 
density gradient was also found (Steinbusch, 1981; 
Soghomonian et al., 1987). This topographic distribution 
was consistant with regional biochemical measurements, 
demonstrating that higher levels of intrastriatal 5-HT 
content or [JH]5-HT uptake is noted in the ventral vs. 
dorsal, and the caudal vs. rostral parts of adult striatum 
(Beal and Martin, 1985; Widraann and Sperk, 1986). Although 
the heterogeneous distribution of the striatal 5-HT 
innervation remains of obscure significance, a complementary 
striatal pattern of the distribution of DA and 5-HT 
terminals has been found in the rostral to caudal, and
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dorsal to ventral axes (Tassin et al., 1976; Doucet et al.,
1986). On the other hand, the striatal 5-HT innervation 
density is ouch less than that of DA fiber innervation 
(Doucet et al., 1986). A critical balance between 
dopaminergic and serotonergic neurons has been postulated to 
underlie normal motor activity, based on biochemical and 
lesion studies (Sourkes and Poirier, 1968).
Lidov and Molliver (1982) reported that 5-HT 
innervation in neonatal rats does not show a mosaic pattern 
of patches and matrix organization, and the major 
development of this innervation takes place 12-15 days after 
birth. This is in contrast with the DA innervation in 
striatum, where at the earlier postnatal stage, the 
prominence of DA islands is found (Olson et al., 1972; Voorn 
et al., 1988).
Serotonin Receptors in Striatum
Based on biochemical, pharmacological and behavioral 
studies, at least seven distinct subtypes of 5-HT receptors 
are currently identified in mammalian central nervous system 
(Frazer et al., 1990; Peroutka et al., 1990; Glennon and 
Dukat, 1991). Many subtypes of this receptor family have 
now been cloned (Julius et al,, 1988; Pritchett et al.,
1988; Albert et al., 1990; Hamblin and Metcakf, 1991; Maricq 
et al., 1991; Voight et al., 1991; Weinshank et al., 1992). 
5-HT, group can be divided into four classes (labeled 5-HT,A
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through 5-HT1D), while the three other groups are designated
5-HT2, 5-HTj and 5-HT4.
There is a relative lack of 5-HT,A receptor in rat 
striatum (Marcinkiewicz et al., 1984; Verge et al., 1986), 
recently confirmed by immunocytochemistry and in situ 
hybridization of the mRNA (El Mestikawy et al., 1991; Riad 
et al., 1991; Chalmers and Hatson, 1991; Miquel et al.,
1991). Autoradiographic studies show that the 5-HT10 
receptor subtype occurs in rat striatum (Pazos and Palacios, 
1985). Destruction of 5-HT innervation to striatum with the
5-HT neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT), results 
in increased striatal [m I]cyanopindolol binding, suggesting 
postsynaptic 5-HTtB sites in the striatum (Offord et al., 
1988; Palacios and Dietl, 1988). 5-HTlD receptors have been 
identified in the brain of rat, guinea pig and other species 
(Herrick-Davis and Titeler, 1988; Herrick-Davis et al.,
1989; Waeber et al., 1990). Quinalinic acid lesion of 
striatal neuronal bodies induces a decrease of 5-HTID 
receptors in substantia nigra, globus pallidus and striatum, 
suggesting that their possible location either on cell 
bodies, dendrites or terminals of interneurons (tfaeber et 
al., 1990). in the striatum, 5-HTj receptors have an 
intermediate density, as determined by autoradiographic 
studies (Pazos et al., 1985a; Palacios and Dietl, 1988). 
Lesion of 5-HT system by 5,7-DHT did not reduce the number 
of 5-HTj sites in rats (Fischette et al., 1987). Therefore,
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it is likely that the 5-HTj receptors are located on non-5- 
HT neurons.
The 5-HTlc receptors were initially found to be present 
at high density in the choroid plexus (Pazos et al., 1985b). 
Since the pharmacological characteristics of this receptor 
subtype are similar to those of 5-HT2 receptors, it was 
suggested that they might be in the same receptor family 
(Hoyer et al., 1988). Autoradiographic studies demonstrated 
that 5-HTic receptors are present at low levels in many 
areas of the brain. But studies of the distribution of the 
mRNA encoding for 5-HT]C receptors confirmed and also 
extended these results (Hoffman and Mezey 1989; Molineaux et 
al., 1989; Mengod et al., 1990), indicating that mRNA and 
binding sites for this particular 5-HT receptor subtype are 
heterogeneously distributed in the rodent brain including 
striatum. It was proposed that 5-HT,c receptors could be 
involved in the regulation of many different brain functions 
(Julius et al., 1988; Hoffman and Mezey, 1989; Mengod et 
al., 1990). The 5-HT,c receptors have been studied more 
extensively in choroid plexus than in any other brain area. 
They appear to be located on epithelial cells where they 
regulate the production and composition of cerebrospinal 
fluid (Pazos and Palacios, 1985). Since lesion of the 
dopaminergic system did not alter 5-HTlc binding in this 
area, it was suggested that this receptor subtype is not 
located on dopaminergic neurons (Palacios and Dietl, 1988).
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Supersensitization of 5-HTlc receptors produced by 5,7-DHT 
lesion, suggested that these receptors are present on non- 
serotonergic neurons (Conn et al., 1987), The postnatal 
development of 5-HTIC receptors has been studied in rat 
brain choroid plexus, although little is known about their 
ontogeny in other brain regions. The number of binding 
sites increases markedly between day 3 and 20 after birth 
(Zilles et al., 1986), and these receptors appear to develop 
earlier than other 5-HT, receptor subtypes. Accompanying a 
2-fold increase in 5-KTlc binding sites in rat brain between 
day 17 and 27 after birth, there is a 5-fold increase in 
corresponding mRNA levels (Roth et al., 1991). The 
mechanisms responsible for regulating 5-HT,c receptors by 
exogenous or endogenous compounds are not currently clear 
(Roth et al., 1990).
5-HTj receptors have been found mainly in brain 
postrema and other brain areas including cortex, amygdala 
and hippocampus, rather than striatum (Kilpatrick et al., 
1987; Barnes et al., 1990). When compared to other 
serotonergic receptors, 5-HTj receptors have a particularly 
low density in the brain. 5-HT4 receptors might belong to 
another functionally important 5-HT receptor family in the 
CNS. So far, the recognition sites for these receptors have 
not been identified because they have been hampered by the 
absence of a high affinity radioligand (Bockaert et al.,
1992).
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6-Hvdroxvdopamine and Dopamine Receptor SupersensItigation
6-hydroxydopamine (6-OHDA), a neurotoxin, selectively 
destroys brain catecholamine-containing neurons and their 
terminals (Breese and Traylor, 1970; Uretsky and Iversen, 
1970; Kostrzewa and Jacobowitz, 1974). 6-OHDA provides a 
pharmacological means to explore central dopaminergic 
function in adult fUngerstedt and Arbuthnott, 1970; Kelly et 
al., 1975; Creese et al., 1977) and developing rats (Breese 
et al., 1984; 1985a; 1985b). In many brain regions, the 
reduction or depletion of a dopaminergic afferent input has 
been shown to result in a functional postsynaptic receptor 
supersensitivity. Lesions of nigrostriatal pathway in adult 
rats produces a motor dysfunction (Breese and Traylor, 1970; 
Ungerstedt, 1971c; Zigraond and Strieker, 1973) and 
behavioral supersensitivity (Ungerstedt, 1971a,b), which is 
accompanied by an increase in the density of DA D3 receptors 
in the denervated striatum (Creese et al., 1977; Staunton et 
al., 1981).
Although neonatal lesioned rats possess the capacity to 
develop apparently normal motor and ingestive behaviors in 
the virtual absence of the emerging DA system (Erinoff et 
al., 1979; Pearson et al., 1980; Bruno et al., 1986), the 
enhanced behavioral responsiveness towards DA D, and D2 
agonists and antagonists has also been well documented after 
lesion with the toxin (Breese et al., 1984; 1985; 1987; 
Duncan et al., 1987). In a series of studies, Breese and
co-workers (1985) demonstrated that the sensitivity of 
neonatal 6-OHDA lesioned rats is often enhanced, with the 
animals becoming particularly sensitive to DA D, agonists. 
This enhanced behavioral responsiveness was not accompanied 
by a change in density (B^) and affinity for either D, or D2 
receptors in the striatum (Breese et al., 1987; Luthman et 
al., 1990), suggesting that the enhanced response to DA 
agonists in neonatal 6-OHDA-lesioned rats could be 
reflecting a change in the sensitivity of secondary and 
tertiary messenger systems linked to the DA recognition 
sites; or an alteration in non-doparainergic neural 
mechanisms which influence the response to DA receptor 
stimulation.
Furthermore, results from the same laboratory showed 
that repeated treatment of neonatal 6-OHDA-lesioned animals 
with SKF 38393, a specific D, receptor agonist (Setler et 
al., 1978), led to a progressive increase in locomotor 
activity and several other behaviors in adulthood, a 
phenomenon referred to as 'priming' (Breese et al., 1985b; 
Criswell et al., 1989). These actions of SKF 38393 were 
blocked by SCH 23390, a specific D( antagonist (Breese et 
al., 1985b; Criswell et al., 1989, 1990). Therefore, 
priming of Dt receptor responsiveness in neonatal 6-OHDA- 
lesioned rats represents a model of a long-term alteration 
in neural function related to repeated activation of a 
receptor system.
Recently, Simson et al. (1992) found that behavioral 
supersensitivity in neonatally lesioned rats was not related 
to the alteration in the activation of adenylate cyclase, 
because no enhancement of cAMP production was observed with 
activation of DA D, receptors in lesioned animals. These 
investigators, however, suggested that differences of 
regionally enhanced electrophysiological sensitivity of 
striatal neurons to Dt agonists and regional distribution 
pattern of tyrosine hydroxylase-like immunoreactivity and c- 
fos-like immunohistochemical expression within the striatum 
of neonatal lesioned rats, might contribute to the unique 
behavioral pattern seen in lesioned rats when they are 
challenged with DA D, agonists in adulthood (Johnson et al., 
1992; Simson et al., 1992).
6-Hvdroxvdopamlne and Serotonin System
Another feature of the 6-OHDA lesion in neonatal rats 
is a substantial increase in the adult striatal levels of 5- 
hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5- 
HIAA) (Breese et al., 1984; Stachowiak et al., 1984). This 
lesion-induced elevation in 5-HT content is associated with 
a corresponding increase in [3H]5-HT uptake (Stachowiak et 
al.,1984) and with a proliferation of 5-HT containing fibers 
in the rostral portion of striatum (Berger et al., 1985; 
Snyder et al., 1986). The same 6-OHDA denervation of 
striatum associated with 5-HT hyperinnervation has also been
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observed in adult lesioned rats and thus it is proposed as 
heterotypic terminal outgrowth, in the sense that it 
involves excessive growth of a neuronal system different 
from that which was lesioned (Zhou et al., 1991). 
Autoradiographic study by Radja et al, (1993) demonstrated 
that 5-HT1B, 5-HTIoeoAB (including 5-HTlc and 5-HT1D), 5-HT2 
receptor subtypes were upregulated in adult rat brain after 
a neonatal 6-OHDA lesion to striatum that is associated with 
5-HT hyperinnervation in that brain region. This 
upregulation of several 5-HT receptor subtypes was likely to 
represent increases in receptor number (B^) rather than the 
affinity of the receptors (Kd) (Radja et al., 1993).
Little is known about the functional implications of 
such striatal 5-HT hyperinnervation and its corresponding 5- 
HT receptor subtype upregulation in lesioned animals. In 
other studies on neonatal 6-OHDA-lesioned rats it was 
reported that the sprouted 5-HT fibers did not seem to have 
an inhibitory control on endogenous 5-HT- and acetylcholine- 
containing neurons (Jackson et al., 1988). Towle et al. 
(1989) found that 5-HT hyperinnervation was not responsible 
for supersensitized locomotor and stereotyped responses to 
either a DA or 5-HT agonist in neonatally lesioned rats, 
although their emphasis was focused on 5-HT2 receptors.
Dopamine System and^Animal_Bohavloral_Models
Denervation supersensitivity models have been widely
used to study central dopaminergic function, to elucidate 
mechanisms of action of DA related agents, and to develop 
models of neurological and psychiatric diseases. As 
measured by a variety of enhanced behavioral changes, the 
mechanism responsible for this phenomenon of denervation is 
supposedly associated with either receptor up-regulation or 
functional changes in second messenger systems with regard 
to these receptors. The best studied animal models are as 
follows.
1. Rotational model. This was first described by Ungerstedt 
(1971a), and was produced by injection of 6-OHDA into one 
substantia nigra of the rat. The resultant unilateral 
lesion of the nigrostriatal pathway leads to a permanent 
depletion of DA in the ipsilateral striatum. Behavioral 
supersensitivity (i.e. contralateral circling) is seen when 
the rat is challenged with a DA agonist. This increased 
sensitivity to agonist administration has been correlated 
with an increase in striatal DA D2 receptor density 
ipsilateral to the lesion (Creese et al., 1977; Hishra et 
al., 1980; Heikkila et al., 1981).
2. Stereotypy model. Tarsy and Baldessarini (1974) 
demonstrated that apomorphine-induced stereotyped behavior 
was increased in rats after prolonged pretreatment with the 
DA synthesis inhibitor, o-methyl-p-tyrosine. This was 
comparable to the effect after chronic administration of 
antipsychotic drugs, suggesting that this behavioral
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stereotypy is probably specifically related to compensatory 
supersensitivity of OA receptors. This stereotypy includes 
sniffing, rearing, licking, gnawing, chewing and locomotion 
behaviors.
3. oral movement model. Rats chronically treated with 
neuroleptics show an increased incidence of purposeless or 
vacuous chewing movements, when challenged by DA receptor 
agonists (Clow et al., 1979; Klawans et al., 1972;
Waddington et al., 1980). This oral activity is similar to 
the oral-bucial-masticatory movements classically described 
in patients with tardive dyskinesia. The phenomenology of 
this oral activity in rats is defined as 'vacuous (or 
abortive or spontaneous) chewing, whereby what appear to be 
robust chewing sequences are manifested, but are not 
directed onto any evident physical material' (Waddington,
1990). In neonatal 6-OHDA-lesioned rats, the effects of a 
D, agonist or D2 antagonist on oral responses are greatly 
potentiated, even though the and Kd for striatal Dt and 
Dj receptor binding do not accompany the marked reduction in 
DA content (Kostrzewa and Hamdi, 1991). This indicates that 
the enhanced oral movements in these neonatally lesioned 
rats are due to supersensitized DA receptors.
4.Catalepsy model. It is one of the classic rodent models 
to induce a state of transient immobility in testing DA 
antagonist activity, which is characterized by placing the 
forepaw of the rat on a testing bar or on an inclined wire
mesh screen and measuring the cataleptic time on the bar or 
the screen (Costall and olley, 1971, Kostrzewa and Kastin,
1993). This effect is mediated by blockade of striatal DA 
receptors (Costall and Olley, 1971; Koffer et al., 1978; 
Heller et al., 1985, Kostrzewa and Kastin, 1993).
Brain Dopamine System and Clinical Diseases
Many clinical diseases are known to be specifically 
related to malfunctioning of DA systems.
Parkinson's disease is a progressive neurodegenerative 
disorder of the basal ganglia. Although characterized 
pathologically by loss of pigmented neurons in the 
substantia nigra, the basic biochemistry of the disease was 
not known until the 1960s. It was found that there is a 
substantial loss of DA in the striatum (Hornykiewicz, 1966). 
It is clear now that the most striking degenerative loss of 
DA neurons occurs in the nigrostiatal system. Studies have 
also been carried out on the relationship between the 
sensitivity of postsynaptic DA receptors and the supply of 
available DA in this disease. Hornykiewicz (1975) reported 
that increased activity of dopaminergic neurons may occur in 
Parkinsonism as a compensation for the decrease of available 
DA at the receptor.
Altered function of mesolimbocortical DA system has 
been implicated in the pathophysiology of schizophrenia.
The disease was once considered to be related to a relative
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excess of central dopaminergic neuronal activity, in view of 
the conviction that antipsychotic agents act therapeutically 
through blockade of central DA transmission (Matthysse,
1973; Snyder, 1982). Increased brain dopaminergic activity 
in schizophrenia could occur through several mechanisms such 
as increased synthesis and release of DA or altered 
sensitivity of DA receptors (Losonczy et al., 1987).
Tardive dyskinesia, characterized by involuntary mouth 
movements, tongue fibrillation and thrusting, occurs in some 
patients who have been taking neuroleptics for long periods. 
This motor disturbance is believed to result from 
compensatory supersensitivity of striatal DA receptors 
(Klawans, 1973). Gilles de la Tourette' syndrome is 
characterized by childhood onset of chronic motor tics and 
involuntary vocalization. The often dramatic response to 
treatment with haloperidol, a DA Dz antagonist, the 
similarity of the movements to those seen in patient with L- 
DOPA intoxication and the disturbed decrease in DA 
metabolism (Snyder et al., 1970; Butler et al., 1979), have 
suggested that excessive DA transmission may have occurred 
in the syndrome. Likewise, changes in DA receptor binding 
and coupling have been reported in Huntington's disease 
(Reisine et al., 1977; Cross and Rossor, 1983; De Keyser et 
al., 1989), which is a genetically determined neurological 
disorder, and associated with a progression of involuntary 
choreiform movements, psychological change and dementia.
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Lesch-Nyhan disease, which is associated with an inborn 
deficiency of the enzyme hypoxanthine-guanine phosphoribosyl 
transferase (Seegrailler et al., 1967) and characterized by 
choreoathetoid movement and hypertonicity (Lesch and Nyhan, 
1964; Wilson et al., 1983), has been found to be related to 
reduced brain DA in children (Lloyd et al., 1981). Because 
treatment of neonatal rats with 6-OHDA resulted in increased 
susceptability for self-mutilation behavior due to the 
destruction of dopaminergic neurons, this useful 
neurochemical model has been proposed for screening of a 
variety of pharmacological agents that could minimize the 
self-mutilation behavior observed in Lesch-Nyhan patients 
(Breese et al., 1984; Breese et al., 1985a,b).
5-HTr Receptor-Related Animal Behaviors and Clinical 
Implications
Recent evidence suggests that although 5-HT,c receptors 
are at high density in the choroid plexus, they are widely 
distributed in the brain and that their activation may have 
numerous behavioral and physiological effects. They may 
thus be implicated in a number of CNS disorders (Julius et 
al., 1988; Holineaux et al., 1989; Mengod et al,, 1990).
1. Locomotor effects: A clear role of 5-HTlc in behavior has 
not yet been established due to the lack of a specific 
agonist for the receptor. However, motor effects were 
reported to be associated with the activation of 5-HT]C
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receptors. The piperazine agonists TFMPP [l-(m- 
trifluoromethylphenyl)piperazine), m-CPP [l-(m- 
chlorophenyl)piperazine] and non-selective ligands, such as 
MK 212 [6-chloro-2-(l-piperazinyl)pyrazine], dose- 
dependently suppress spontaneous locomotor activity in rats 
(Kennett and Curzon, 1988a; Lucki et al., 19S9; Klodzinska 
et al., 1989). This effect was found to be prevented only 
by 5-HT antagonists with high affinity for 5-HTtc receptors, 
such as metergoline and mianserin, suggesting specific 
involvement of these receptors.
2. Feeding: Systemic administration of m-CPP and TFMPP 
reduces food intake in freely feeding rats (Kennett et al.,
1991). Studies with 5-HT antagonists suggested that this 
hypophagic effect is mediated by activation of 5-HT,c 
receptors, though activation of 5-HTtB sites was also needed 
for the response to occur (Kennett and Curzon, 1988b). 
Dourish et al. (1989) proposed that postsynaptic 5-HTtc 
receptors located in the ventromedial hypothalamus play an 
important role in regulating feeding.
3. Psychiatric disorders: Administration of m-CPP in normal 
human volunteers has been reported to increase feelings of 
anxiety, dysphoria and panic (Charney et al., 1987; Murphy 
et al., 1989). Anxiogenesis was indicated by both decreased 
social interaction and decreased activity in rats (Kennett 
et al., 1989). These effects might be related to 5-HT]c 
receptors, because they are blocked by mianserin,
metergoline and cyproheptadine (i.e., compounds with high 
affinity for the 5-HT,c receptor) .
4. Hypertonic saline consumption: Administration of 
fenfluramine, fluoxetine, m-CPP, or MK 212 decreases 
hypertonic saline intake at doses that have negligible 
effects on water or physiological saline consumption (Neil 
and Cooper, 1989). Since the more selective 5-HT,,, agonist 
CGS 12066B (7-trifluoromethyl-4(4-ethyl-l-pipera2inyl)- 
pyrrolofl,2-alquinoxaline] has no such an effect, 5-HT,c 
receptors have been suggested to be involved in mediating 
salt-drinking behavior. Further pharmacological 
characterization of this effect is necessary.
5. Migraine effect: Recent evidence indicates that 
ergotamine and dihydroergotamine, two effective antimigraine 
agents, are potent 5-HT,c receptor antagonists in piglet 
choroid plexus (Brown et al., 1991). Therefore, it is 
suggested that 5-HT,c receptors may play a role in 
initiating migraine attacks (Fozard and Gray, 1989).
The above findings of so many potential roles for 5- 
HT,C receptors suggest that the effects of many drugs acting 
on brain 5-HT systems might have been targeting on these 
particular receptor sites. The availability of more 
selective tools will clarify the roles of 5-HT,c receptors 
in behavior and in CNS diseases.
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Rational*
The availability of 6-OHDA to destroy brain DA- 
containing neurons in both adult and neonatal rat provides a 
pharmacological means to study motor functions and lesion- 
related biochemical changes that may depend on the age at 
which the dopaminergic pathway is destroyed (Breese and 
Traylor, 1970, 1972; Smith et al., 1973; Breese et al.,
1984, 1985b). Treatment of adult rats with 6-OHDA produces 
a profound motor dysfunction such as aphagia, adipsia and 
akinesia (Breese and Traylor, 1970; Ungerstedt, 1971c; 
Zigmond and Strieker, 1973). In contrast, neonatal 
treatment of rats with the toxin does not result in such an 
acute motor syndrome despite the fact that near-total 
destruction of this emerging DA system is produced (Erinoff 
et al., 1979; Bruno et al., 1986; Duncan et al., 1987). 
However, these rats exhibit an increased susceptibility for 
self-mutilation behavior (Breese et al., 1984, 1985a,b).
Clinically, Parkinson's disease is associated with 
reduced brain DA and motor dysfunction (Hornykiewicz, 1973), 
and Parkinsonian patients display tremor, bradykinesia and 
rigidity. Another disorder related to the same brain 
biochemical difficiency is Lesch-Nyhan syndrome. The latter 
syndrome is characterized by choreoathetoid movement, 
hypertonicity and unique compulsive self-mutilation of 
digits and tissue about the mouth (Lesch and Nyhan, 1964).
It is believed that the adult 6-OHDA-treated rat serves as a
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neurochemical model for Parkinson's disease (Ungerstedt, 
1971), whereas the neonatal lesioned rat provides a model 
for central dysfunctions observed in childhood diseases, one 
of which is Lesch-Nyhan syndrome (Breese et al., 1984,
1985a,b).
Neonatal 6-OHDA-lesioned rats are also known to be 
supersensitized to DA D, receptor agonists in the absence of 
an altered density and affinity of the receptor. SKF 38393, 
a selective D, agonist, produces marked changes in 
stereotyped and locomotor behaviors in the neonatal lesioned 
rats (Breese et al., 1984, 1985a,b, 1987). This change in 
sensitivity is a latent one, which must be unmasked by 
repeated doses of SKF 38393. This is referred to as a 
'priming' phenomenon (Criswell et al., 1989). Priming of 
neonatal 6-OHDA-lesioned rats has been implicated in 
learning, development of craving following repeated intake 
of some drugs, or the appearance of motor disturbances 
following prolonged administration of drugs that influence 
dopamine receptor functions (Criswell et al., 1989, 1990). 
Hamdi and Kostrzewa (1991) demonstrated that the D, receptor 
could be ontogenetically sensitized by repeated treatments 
with a D, agonist during development. As in adult-primed 
rats, there were enhanced D, agonist-induced stereotyped 
behaviors in adulthood. In order to further investigate 
ontogenetic sensitization of neonatal 6-0HDA-treated rats 
and examine its underlying biochemical association, the
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selective D, receptor agonist, SKF 38393, was used alone, or 
in combination with neonatal 6-OHDA lesion during postnatal 
ontogeny in this study.
This project was thus undertaken with the objective of 
(1) assessing the degree or extent of ontogenetic 
sensitization of neonatal 6-OHDA-lesioned rats by repeated 
treatments of the animals with a DA D, agonist in 
development (2) investigating the status of dynamics of the 
DA Dt receptors, such as high and low affinity binding sites 
in the neonatal 6-OHDA-lesioned rat model, or in neonatal 6- 
OHDA-lesioned rats repeatedly treated in postnatal ontogeny 
with SKF 38393 (3) evaluating the association of D,
receptors with second messenger systems in the above animal 
models, and also (4) determining mRNA levels for D, 
receptors in these rat models.
The above investigations can lead to a better 
understanding of whether ontogenetic DA D, agonist 
treatments modulate the behavioral responses in adult rats 
that were lesioned neonatally with 6-OHDA. These studies 
would also resolve the problem of whether several 
biochemical markers would be associated with the enhanced 
behavioral responses generated by a neonatal chemical lesion 
or combined neonatal lesion plus ontogenetic DA D, agonist 
treatments.
Moreover, in neonatal 6-OHDA-lesioned rats, acute 
treatment with a DA D, receptor agonist results in a great
potentiation of the incidence of oral activity, even though 
the and Kd for striatal Dj receptor binding do not 
accompany the marked reduction in DA content (Kostrzewa and 
Hamdi, 1991}. It is likely that the enhanced oral response 
in neonatal 6-OHDA-lesioned rats is due to supersensitized 
D, receptors, since the striatal DA depletion in neonatal
6-OHDA-treated rats is accompanied by elevation in 5-HT 
levels (Breese et al., 1984; Stachowiak et al., 1984;
Luthman et al., 1987), hyperinnervation of rostral striatum 
by 5-HT-containing fibers (Berger et al., 1985; Snyder et 
al., 1986), and upregulation of several 5-HT receptor 
subtypes in striatum (Radja et al., 1993), it is reasonable 
to study possible interactions between DA and 5-HT 
neurochemical systems in the Dt supersensitized induction of 
oral activity by using this animal model.
Another aim in the present project, therefore, was to 
evaluate whether 5-HT receptors were involved in the 
induction of supersensitized oral responses in neonatal 6- 
OHDA-lesioned rats. The piperazine compound, m-CPP, was 
used in this study, because this 5-HT receptor agonist was 
found to induce oral activity in intact rats (Stewart et 
al., 1989). A series of other 5-HT agonists and antagonists 
was also used to determine which probable 5-HT receptor 
subtype would be related to such involvement. This study 
should provide evidence of whether there is a functional 
correlation between DA D, receptor and 5-HT fiber
innervation of the striatum.
Chapter 2 
Materials and Methods
Animals and Treatment
Timed-pregnant Sprague-Dawley derived albino rats were 
obtained from Charles River Laboratories (Research Triangle, 
NC) approximately 1 week before delivery. Animals were 
housed singly in clear Perspex cages in a room with 
controlled temperature (22 ± 1 °C) and lighting (12 h-12 h 
light-dark cycle, lights on at 07:00), and had free access 
to food and water. Date of litter delivery was noticed 
within 12 hours and the date of birth was considered as day
0. At birth, litters were reassigned, so that each dam had 
rats from several litters, with each reconstituted litter 
consisting of a maximum of ten pups.
Starting at birth all pups were treated once a day for 
28 consecutive days by intraperitoneal (i.p.) injection of 
SKF 38393 HCl (l-phenyl-2,3,4,5-tetrahydro-[lH]-3- 
benzazepine-7,8-diol hydrochloride; 3.0 mg/kg, salt form; 
Research Biochemicals, Inc., Natick, MA) or saline vehicle. 
At 3 days from birth all rats also received a bilateral 
intracerebroventricular (i.c.v.) injection of 6-OHDA 
hydrobromide (100 /jg, salt form, on each side; Regis 
Chemical Co., Chicago, IL) or the vehicle, saline-ascorbic 
acid (0.1%). Neonates were pretreated with desipramine (20 
mg/kg i.p.) 1 hr before 6-OHDA injection to prevent
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destruction of noradrenergic neurons, starting 3 days after 
birth, all animals were divided into four treatment groups: 
(1) saline (2) SKF 38393 (3) 6-OHDA (4) SKF 38393 plus 6- 
OHDA. At the age of 6 weeks, the first portion of the rats 
from each group was challenged with SKF 38393, to study (1) 
locomotor activity and (2) stereotyped behaviors (see 
behavioral observations). These rats were continuously 
tested with a weekly challenge dose of SKF 38393 for another 
three weeks. At 9 weeks of age, a second portion of the 
rats from all treatment groups without weekly challenge dose 
of SKF 38393 in adulthood, was sacrificed for biochemical 
analyses only.
At 3 and 9 months of age, another two separate groups 
of rats consisting of neonatal saline and 6-OHDA treatment, 
respectively, were used for determination of oral activity 
response to DA D, agonist and antagonist as well as a series 
of 5-HT receptor agents.
All animals were sacrificed by decapitation. Brains 
were immediately removed and the striata were dissected 
free, quickly frozen on dry ice, and stored at -70 °c for 
later in vitro neurochemical assessments (see biochemical 
assays below).
Behavioral Observations
1. Locomotor activity. Between 6 and 9 weeks of age, rats 
were placed singly in donut-shaped test chambers (46 cm in
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diameter) with six equidistant markings along the 
circumference. After a 60 min habituation period in a quiet 
and well-lighted room, a challenge dose of SKF 38393 HCl 
(3.0 mg/kg i.p., salt form) or vehicle was administered. 
Locomotor activities were then videotaped by a camcorder for 
60 min starting 10 min after the challenge agent. Tapes 
were replayed and the distance traveled by each rat was thus 
determined.
2. Stereotyped behaviors. At 8 weeks of age, rats were 
placed singly in clear Perspex cages (48 x 26 x 18) with 
wood chip bedding, in a quite and well-illuminated room, and 
were acclimated to the testing surroundings for 30 min. An 
individual rat was challenged first with saline vehicle 10 
min before behavioral testing. The rat was then observed 
for stereotyped behaviors for 10 min. A challenge dose of 
SKF 38393 HCl (3.0 mg/kg i.p., salt form) was then 
administered and rats were again observed for 10 min for 
stereotyped behaviors, starting 10 min after injection. 
Behaviors were quantified as seconds in which each 
particular behavior was performed by a rat. Therefore, the 
total time an individual rat spent in performing or not 
performing an activity was 600 seconds (10 min observation 
period). The behaviors observed were locomotion, sniffing, 
grooming, eating, taffy pulling (coordinated movement of 
front paws toward the mouth and then away from the body), 
digging, gnawing, licking, jumping, paw treading and
locomotion. Yawning and rearing were counted as numbers of 
incidents, not seconds. Immobility was defined as the time 
period in which a rat was not observed in any stereotypic 
activity.
3. Oral activity: Rats were observed for oral responses to 
test agents between 3 and 9 months of age. For each test 
session, rats were placed in individual clear plastic cages 
(48 x 26 x 18 cm) with steel grid floors in a quiet, well- 
ventilated and well-lighted room. Rats were allowed to 
acclimate to the new environment for at least 1 hr.
Between 9:00 A.M. and 4:00 P.M. each rat was given a 
single i.p. or s.c. treatment with vehicle, SKF 38393 HC1 
{0.03-3.0 mg/kg i.p.),* m-CPP 2HC1 [l-(3- 
chlorophenyl)piperazine dihydrochloride, o.5-8.0 mg/kg
i.p.]; CGS 12066B maleate {7-trifluoromethyl-4(4-ethyl-l- 
piperazinyl)-pyrrolo[l,2-alquinoxaline], 1:2 maleate salt,
3.0 mg/kg i.p.}; or 8-0H-DPAT HBr [(±)-8- 
hydroxydipropylaminotetralin hydrobromide, 0.1 mg/kg s.c.]. 
Each rat was then observed one at a time, for 1 min every 10 
min, over a 60-min period, beginning 10 min after any of 
these treatments. Numbers of rapid jaw movements were 
counted. Some rats were pretreated with mianserin HC1 (1.0 
mg/kg s.c., 30 min); ketanserin tartrate (5.0 mg/kg i.p., 30 
min); MDL 72222 (3-tropanyl-3,5-dichlorobenzoate, 10.0 mg/kg 
s.c., 30 min); or SCH 23390 HCl [R-(+)-7-chloro-8-hydroxy-3- 
methyl-l-phenyl-2,3,4,5-tetra-hydro-lH-3-benzazepine
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hydrochloride, 0.30 mg/kg i.p., 1 hr]. At least 1 week 
intervened between these observation sessions.
Oral activity in these studies is of the type described 
by Haddington (1990) as "vacuous (or abortive or 
spontaneous) chewing, whereby what appear to be robust 
chewing sequences are manifested, but are not directed onto 
any evident physical material." No differentiation between 
lateral and vertical jaw movements was made. Also, there 
was occasional tongue thrusting noted in the these rats.
Oral activity that occurred in eating, grooming or taffy 
pulling was not counted.
petemination of Pa,_5-HT_*na_Thelr_Hetabolites in the 
Striatum
Striatal concentrations of DA, 5-HT and their 
metabolites were measured by liquid chromatography with 
electrochemical detection as follows. The striata were 
sonicated in 1 ml of 0,1 H trichloroacetic acid containing 
0.2 mg/ml cysteine as a stabilizing agent and an internal 
standard which was 0.2 nmol/ml 5-hydroxyindole carboxylic 
acid (5HICA). The resulting homogenate was centrifuged at
12,000 x g for 5 min and DA, homovanillic acid (HVA), 3,4- 
dihydroxyphenylacetic acid (DOPAC), 5-HT and 5- 
hydroxyindoleacetic acid (5-HIAA) were assayed by injecting 
30 nl of supernatant directly onto the C18 analytical 
column. The column was an Econosphere CIS (5 micron, 4.6 x
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150 ram) from Alltech Associates. The mobile phase was 0,1 M 
monochloroacetic acid, 1 raM EDTA, 220 mg/1 sodium 
octanesulfonic acid, 8% acetonitrile, pH 2.6 at a flow rate 
of 1.3 ml/min and temperature of 40 °C.
The instrumentation consisted of a Bioanalytlcal System 
LCEC Analyzer and a Waters WISP automatic sample injector 
with a refrigrated sample compartment (samples kept at 5°C). 
The glassy carbon electrode was used at a potential of +0.75 
volts. Peak heights and sample concentration were 
calculated with a Hewlett-Packard HP1000 chromatography data 
system.
Determination of da competition for f^iscH 23390 Binding to 
striatal Homogenates
To assess DA competition for [3H]SCH 23390 binding, a 
modified method of Hess et al. (1986) was used. Briefly, 
striata were homogenized with a Teflon on glass mortar and 
pestle, in 100 volumes of ice cold 50 mM Tris buffer (pH 
7.4). This gentle homogenizing procedure was used to avoid 
destruction of Dt receptors during this tissue preparation 
step (Norman et al., 1989). Homogenates were then 
centrifuged at 35,100 x g for 10 min at 4 °C using a Beckman 
J2-21M centrifuge and JA-20.1 rotor. After one wash, the 
homogenates were preincubated at 37 °c for 15 min, chilled 
in ice and centrifuged as before. Tissue pellets were 
finally resuspended in 200 volumes of fresh buffer.
Aliquots (300 pi) of homogenates were added to 450 pM 
of [3H]SCH 23390 (specific activity 294 mCi/mg; Amersham, 
Arlington Heights, IL) in Tris buffer containing 120 mM 
NaCl, 5 mM KCl, 2 mM CaCl2, 0.1% ascorbic acid, 10 pM 
pargyline (final concentrations) and varying concentrations 
of DA as competitor (1 nM - 1 mM), to yield a 2.5 ml final 
assay volume. Samples were incubated for 40 min at 37 °C in 
a shaking water bath, and then were rapidly filtered under 
partial vacuum on Whatman GF/F glass fiber filters using a 
Millipore filtration unit. Filters were washed 3 times with 
5 ml of ice-cold Tris-salt solution each time. After drying 
overnight, filters were placed in 9 ml of fluor, and tritium 
activity was determined in a Beckman LS 9800 liquid 
scintillation spectrometer. A GraphPad program (GraphPad 
Software Inc., San Diego, CA), using a nonlinear regression 
model for complex ligand-receptor binding systems, was used 
to fit the agonist-antagonist competition curves matching 
two binding sites. The ICjo values for DA at the high and 
low affinity site and the percentage of each receptor 
binding component were estimated by the computer program.
The K, for each ICi0 was determined according to following 
equation:
ICm
K, = --------------
1 + L / Kj
where L is the concentration of [JH]SCH 23390 and Kd is its 
affinity for the receptors.
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Determination of mRNA Levala for Pt and 5-HT,,. Receptors in 
the Striatum
Two mixtures of 48-base oligonucleotide probes for the 
respective rat DA D, and 5-HT,c receptor mRNA were used (NEN 
Research Products, Boston, MA). The sequences for D( 
receptor mRNA are complementary to bases 13-60 (5'-GAA ATC 
CCT CTC CGC TGG CAG CCC GGC CTC ATC CAT GGT AGA AGT GTT-3'),
520-567 (5/-GGA CTG CTG CCC TCT CCA AGG CTG AGA TGC CCC GGA
TTT GCT TCT GGG-3') and 664-711 (5'-TGT CAC ACT TGT CAT CCT 
CGG TGT CCT CCA GGG AGG TAA AAT TGC CAT-3'), while the 
sequences for 5-HTlc receptor mRNA are complementary to 
bases 4-51 (5'-GCC GAT TAG GTG CAT CAG GAG CGA GCG CAC CGC 
GTT GCC AAG GTT CAC-3'), 721-768 (5'-CTC CTC GGT GTG ACC TCG 
AAG TAA CAT CAG AGT TTG ACG GCG CAG GAC-3') and 856-903 (5'-
GGT GCC TCT GGG ACG CTT TTG TTT CTT CTT TCG ACG TGG TTT CTG
ATC-3').
Rat striatal tissues from above treatment groups were 
homogenized in denaturing solution containing 4.0 M 
guanidine thiocyanate, 42 mM sodium citrate, 0.83% N-lauroyl 
sarcosine and 0.2 mM B-mercaptoethanol, using a Tekmar 
Tissuraizer (setting 5, 20 sec). After adding 2.0 M sodium 
acetate (pH 4.0), the homogenates were extracted with equal 
volume of phenol:chloroform:isoamyl alcohol mixture and then 
centrifuged at 10,000 x g (20 min at 4 °C). The upper 
aqueous phase was collected and the total RNA was 
precipitated with isopropanol by centrifugation. RNA was
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quantified by UV spectrophotometry at 260 nm wavelength.
A sample representing 5-10 fig of striatal RNA denatured 
at 95 °C for 2 min, was fractionated by electrophoresis on 
1% agarose gel containing 2% formaldehyde, 20 mM 3-(N- 
morpholino)propanesulfonic acid, 5 mM sodium acetate and 1 
mM EDTA. The gel was stained with ethidium bromide and 
visualized under UV light to check the integrity and loading 
of the RNA in each lane. The RNA was then transferred to 
nylon membranes (Schleicher & schuell, Keene, NH), which 
were subsequently crosslinked under UV light for 5 min and 
baked at 80 °C for half an hour. Some of the striatal RNA 
samples from each treatment group were denatured in 7.4% 
formaldehyde at 65 °C and then transferred directly to nylon 
membrane on an apparatus for dot blot analysis. The 
membranes were probed with respective D, and 5-HTlc receptor 
mRNA probe according to following procedure.
Membranes were incubated for l hr at 58 °C in 20 ml of 
prehybridization buffer containing 5 x SSC, 20 mM Na2HP04, 7% 
SDS, l x Denhardt's solution and 100 fig/ml denatured salmon 
sperm DNA. Following prehybridization, the buffer was 
replaced with the same new fresh buffer and the membranes 
were hybridized with oligonucleotide probes at 58 °C for 24 
hr, which were end-labelled with [r-HP]ATP using 
oligonucleotide 5'-end labelling system (Promega 
Corporation, Madison, WI). The membranes were washed twice 
in 2 x SSC, 1% SDS and 20 mM Na2HP04 at room temperature for
15 rain. They were finally washed twice in 0.5 x SSC and 1% 
SDS at 58 °C for 15 min and then were exposed to Kodak X- 
OMAT AR film (Sigma Chemical Co., St. Louis, MO} at -70 °C 
with two intensifying screens for 48-72 hr to ensure that 
the exposure time was within the linear range of the film. 
The optical densities of the bands or the dots were measured 
by a Bio Image Analysis system (Millipore Corporation 
Imaging systems, Ann Arbor, MI). The probes were removed 
from the membranes by washing in solution containing 50% 
formamide and 2 x SSPE buffer at 65 °C for 1 hr before 
rehybridization with cDNA probe for B-actin mRNA. The B- 
actin mRNA probe was labelled with [a-JIP]dCTP by a Prime-a- 
Gene labelling system (Promega Corporation, Madison, WI) to 
give a specific activity of 1-2 x 109 cpm per fig of DNA.
The B-actin mRNA measurements were used mainly for 
correcting errors that occurred in preparation or loading of 
the RNA samples.
Determination of DA-fltimulated Adenvlate Cyclase Aetivitv in 
the Striatum
The striatal tissues from all above treatment groups 
were homogenized with a Teflon on glass mortar and pestle, 
in 50 volumes of ice-cold 10 mM Tris maleate/2 mM EGTA 
buffer (pH 7.4). Homogenates were then centrifuged at 
35,100 x g for 10 min in Beckman model J2-21M superspeed 
centrifuge, using a JA-20.1 rotor. After one wash with the
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same buffer and centrifugation as before, the resultant 
pellet was resuspended in 70 volumes of fresh buffer and 
kept on ice prior to use for adenylate cyclase activity 
assays.
Adenylate cyclase activity was assayed in a 200-jil 
incubation mixture containing 80 mM Tris maleate, 0.4 mM 
EGTA, 4.0 mM MgS04, 1.0 mM isobutylmethylxanthine, 5.0 mM 
phosphocreatine, 50 unit/ml creatine phosphokinase, 0.02% 
ascorbic acid, 10 juM pargyline, 0.1 mM GTP, 50 nM spiperone, 
and varying concentrations of DA (0-10° M). In some 
instances, 12.2 /iM forskolin or 10 mM NaF in combination 
with 10 jiM Alcl3 ([A1F4)‘), was added to the mixture instead 
of DA, in order to stimulate the catalytic subunit of the 
enzyme or the Ns protein, respectively. Spiperone was 
included in all incubation solutions to block DA D2 
receptor-mediated inhibition of adenylate cyclase activity. 
Membrane suspensions (30-40 /ig protein) were preincubated at 
30 °C for 5 min in the reaction mixture. The reaction was 
then started by adding ATP (final concentration: 1.0 mM) and 
the mixtures were incubated at 30 °c for 15 min. After 
termination of the reaction in boiling water for 4 min, the 
mixtures were centrifuged at 13,000 x g for 5 min. Aliquots 
of the supernatant were assayed for cAMP content using an 
Amersham cAMP enzymeimmunoassay kit (RFN 225, Amersham, UK; 
sensitivity: 38.4 pg/ml). Protein content of striatal 
homogenates was determined by the method of Lowry et al.
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(1951).
Data Mialvaia
Locomotor activity: Data are expressed as the mean 
distance (meters) ± S.E.M. in different groups of rats 
traveling within activity testing chambers. The statistical 
significance of the data was determine by a two-way analysis 
of variance (ANOVA), followed by a post-ANOVA Newman-Keuls 
test. A p value of < 0,05 was considered to be 
statistically significant.
Stereotyped behaviors: Results are expressed as the 
mean time (seconds) ± S.E.M. in which rats from different 
treatment groups perform a particular behavior. The 
statistical significance of the results was evaluated by a 
one-way ANOVA, followed by a post-ANOVA Newman-Keuls test. A 
p value of < 0.05 or smaller was considered to be 
statistically significant.
Oral activity: Results are expressed as the mean number 
of oral movements ± S.E.M. of rats receiving neonatal 6-OHDA 
treatment or vehicle. The statistical significance was 
determined by a one-way ANOVA, followed by a post-ANOVA 
Newman-Keuls test. A p value of < 0.05 or smaller was 
considered to be statistically significant.
Monoamine determinations: The mean nanomoles of 
monoamine or metabolite per gram of tissue ± S.E.M. in 
different treatment groups were analyzed by the ANOVA, 
followed by a post-ANOVA Newman-Keuls test, in order to
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determine the statistical significance among treatment 
groups. A p value of < 0.05 was considered to be the level 
for statistical significance.
Binding studies: Competition curves were analyzed 
according to models for the competition of radioligand and 
competitor, DA, to one or two binding sites. The 
statistical difference between models was tested by 
comparing the sum of squares which resulted from different 
fits of the data. A sequential F-test was used according to 
the following equation:
SS, - SS,
df, - df,
F = ------------
ssa
df,
where SS refers to the sum of squares, and df refers to the 
number of degree of freedom. The subscrit 1 and 2 refer to 
the model for one, and two binding sites, respectively. A 
model for two binding sites was retained only when it fitted 
the data statistically significantly better than a model for 
one binding site (p < 0.05). Also, the mean (+ S.E.M.) 
percent of high affinity binding sites (%RH), and the 
respective mean (± S.E.M.) KH and KL in each treatment group 
were analyzed by one-way ANOVA. A p value of < 0.05 was 
considered to be the level for statistical significance.
mRNA analyses and adenylate cyclase activity assays:
The mean {± S.E.M.) ratio of D( or 5-HTIC receptor mRNA to JJ-
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actin mRNA, and mean (± S.E.M.) picomoles of cAMP per 
milligram of protein per min, respectively, were analyzed by 
ANOVA, followed by a post-ANOVA Newman-Keuls test, in order 
to evaluate the statistical significance among different 
treatment groups. A p value of < 0.05 was considered to be 
the level for statistical significance.
Chapter 3 
Results
DA D1 Receptor Bupersensltlvitv
Locomotor activity of rats
Starting at 6 weeks adult rats from the different 
treatment groups were tested at weekly intervals for 
spontaneous and SKF 38393-induced locomotor activity. At 6, 
7 and 9 weeks there was little locomotor activity in each 
group after administration of saline, and no statistically 
significant difference between the groups (p > 0.05, left 4 
bars in figs. l, 2 and 3).
At 6, 7 and 9 weeks, SKF 38393 HC1 treatment (3.0 mg/kg 
i.p.) did not increase locomotor activity in the vehicle 
control rats, nor in the rats treated repeatedly during 
development with SKF 38393 HCl (3.0 mg/kg per day x 28 days 
from birth, i.p.; Fig. 1, 2 and 3, 5th and 6th bars). At 6 
weeks acute SKF 38393 HCl treatment (3.0 mg/kg i.p.) 
produced a slight increase in locomotor activity in the 
group of rats that was lesioned at 3 days after birth with 
6-OHDA HBr (200 jig, i.c.v.), although this effect was not 
different from that after saline treatment (fig. 1, 7th 
bar). However, in the group of rats that was both lesioned 
at 3 days after birth with 6-0HDA and treated repeatedly in 
development with SKF 38393 HCl (3.0 mg/kg per day x 28
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days), acute SKF 38393 treatment at 6 weeks produced a large 
increase in locomotor activity (p < 0.05, fig. 1, 8th bar). 
Rats in this group traveled about 210 meters in 1 hr, vs. 
about 40 meters for the 6-OHDA-lesioned group (p < 0.05, 8th 
vs. 7th bar of fig. 1). The greater SKF 38393-induced 
activity in this group suggests that ontogenic SKF 38393 
treatments produced homologous sensitization of the DA 
receptors.
One week later when rats were challenged again with SKF 
38393, there was an increase in locomotor activity in the 2 
groups of rats lesioned at 3 days after birth with 6-OHDA.
In the group treated at 3 days with 6-OHDA, locomotor 
activity increased substantially from one week before, now 
155 meters in the one hour following the challenge dose of 
SKF 38393. In the group that was lesioned with 6-OHDA at 3 
days and also treated repeatedly in development with SKF 
38393, the challenge dose of SKF 38393 at 7 weeks increased 
the distance traveled to more than 590 meters, nearly triple 
that from the week before (8th bar of fig. 2 vs. 8th bar of 
fig. 1).
In the 8th week rats were tested for stereotyped 
activities following the SKF 38393 injection, so there is no 
locomotor activity data. In the 9th week the challenge dose 
of SKF 38393 produced more than a 2-fold increase in 
locomotor activity in the group of rats lesioned at 3 days 
after birth with 6-OHDA (p < 0.05, 7th bar of fig. 3 vs 7th
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bar of fig. 2). However, in rats receiving both 6-OHDA and 
SKF 38393 treatments in development, the challenge dose of 
SKF 38393 at 9 weeks increased the distance traveled only 
slightly and not significantly from that at 7 weeks (8th bar 
of fig. 3 vs. 8th bar of fig. 2). Nevertheless, SKF 38393- 
induced locomotor activity in this group was higher at 9 
weeks vs. 6 weeks (p < 0.05, 8th bar of fig. 3 vs. 8th bar 
of fig. 1).
Stereotyped behaviors of rata
At 8 weeks, following a saline injection, there was 
little stereotyped activity in the 4 groups of rats, with 
immobility time being 340 to 490 seconds (i.e., 600 seconds 
of observation, table 1 ). Following the challenge dose of 
SKF 38393 HCl (3.0 mg/kg i.p.) activity increased in all 
groups (table 2). However, for rats treated repeatedly in 
development with SKF 38393, there was no difference from 
control for time spent in sniffing, locomotion, grooming, 
eating, taffy pulling, digging, gnawing and paw treading, 
following the challenge dose of SKF 38393 at 8 weeks. Also, 
numbers of yawns and rearings was not different between 
these two groups.
In the group of rats lesioned at 3 days with 6-OHDA, 
the challenge dose of SKF 38393 at 8 weeks substantially 
increased time in locomotion (351.7 ± 59.6 vs. 1.7 ± 0.9 
sec) and paw treading (89.0 ± 50.2 vs. 0.0 sec), compared to
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the vehicle control group (all p < 0.05, table 2). 
Conversely, in the 6-OHDA vs. control group, the challenge 
dose of SKF 38393 decreased time in grooming (4.3 ± 4.3 vs. 
135.4 ± 21.8 sec), gnawing (1.1 ± 0.7 vs. 12.1 ± 2.3 sec) 
and immobility (84.1 ± 56.3 vs. 396.1 ± 34.4 sec) (all p <
0.05, table 2).
In the group of rats lesioned at 3 days with 6-OHDA and 
also treated daily for the first 28 days from birth with SKF 
38393 HCl (3.0 mg/kg per day, i.p.), the challenge dose of 
SKF 38393 at 8 weeks produced several changes in stereotyped 
behaviors. Time in locomotion (228.9 ± 74.8 sec), taffy 
pulling (172.5 ± 87.8 sec) and paw treading (140.3 ± 75,8 
sec) was increased vs. the control group (p < 0.05); taffy 
pulling was different vs. the 6-OHDA group (p < 0.05, table 
2). Time in grooming (3.5 ± 3.5 sec) and immobility (0.0 
sec) were different vs. control (p < 0.05); while immobility 
time was different vs. the 6-OHDA group (p < 0.05).
Striatal levels of DA. DOPAC. HVA, 5-HT and 5-HIAA
As shown in table 3, neonatal 6-OHDA treatment produced 
a profound depletion of DA (>99% reduction), DOPAC (>99% 
reduction) and HVA (>99% reduction) in the striatum of rats. 
Conversely, neonatal 6-OHDA treatment was associated with a 
70% increase in striatal 5-HT and 35% increase in 5-HIAA 
content (all p < 0.001). SKF 38393 treatments for the first 
28 days after birth did not produce an effect on striatal
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levels of DA, 5-HT and their metabolites, nor did this 
treatment modify the effect of 6-OHDA.
Agonist competition for PA D1 receptor binding in striatal 
baBpq<nn**g
Computer-modeled DA agonist-[sH]SCH23390 antagonist 
competition binding curves are shown in figs. 4-7 for the 
respective groups receiving saline, ontogenetic SKF 38393 
and/or neonatal 6-OHDA treatments. Each curve fits a two- 
site model. Dissociation constants to high affinity (RH) 
and low affinity (RL) have been designated KH and KL, 
respectively. Table 4 summarizes computer-assisted binding 
parameters for DA competition curves, demonstrating that 
these curves exhibit high and low affinity binding 
components. No apparent difference was observed in the 
distribution of high and low affinity agonist binding sites 
between 6-OHDA vs. saline group. Also, there was no 
significant effect of ontogenetic SKF 38393 treatments on 
the affinity of DA at either high or low affinity states of 
the receptor. Postnatal treatment of 6-OHDA lesioned rats 
with SKF 38393 for 28 consective days likewise did not 
affect high or low affinity agonist binding sites.
Striatal levels of DA Dl receptor mRNAs
Dot blot analysis revealed that in the first portion of 
rats that did not receive weekly challenge doses of SKF
52
38393 in adulthood, striatal mRNA levels for DA D, receptor 
were significantly reduced (p < 0.05) in neonatal 6-0HDA- 
lesioned rats, regardless of whether ontogenetic SKF 38393 
treatments were given (fig. 8A). SKF 38393 treatments for 
the first 28 days after birth per se did not produce an 
effect on striatal mRNA content of the D, receptor (fig.
8A). In the second portion of rats receiving weekly adult 
challenge doses of SKF 38393, the striatal mRNA levels for 
D, receptors in neonatal 6-OHDA-treated rats were restored 
to the control level, so that there was no statistically 
significant difference in D, receptor mRNA content among the 
treatment groups (fig. 8B).
Striatal DA-atimulated adenylate cyclase activity
No significant difference in basal adenylate cyclase 
activity was observed between treatment groups (fig. 10). 
Stimulation of D( receptors by DA significantly increased 
adenylate cyclase activity in the striatum at higher doses 
of DA (lO^-lO*1 M) in all treatment groups. The relative 
increase among saline, SKF 38393, 6-OHDA, and /SKF 38393 + 
6-OHDA' treatment groups was similar (fig. 9). To evaluate 
the effects of neonatal 6-OHDA and ontogenetic SKF 38393 
treatments on the receptor coupling with G-protein, NaF was 
used to stimulate Ns. The adenylate cyclase activity was 
enhanced by NaF, but there were no statistical differences 
among the treatment groups (fig. 10, p=0.05l). To examine
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the effects of neonatal 6-OHDA and ontogenetic SKF 38393 
treatments on the activity of adenylate cyclase, the enzyme 
was stimulated directly with forskolin. The activity of 
adenylate cyclase was markedly increased by forskolin. 
However, no significant difference was found in the 
treatment groups of saline, SKF 38393, 6-OHDA, and SKF 38393 
plus 6-OHDA (fig. 10, p=0.759).
Mediation of PA Agonist-induced Oral Behavior 
bv the Serotonin System
Dose-response study of SKF 38393-induced oral activity
To determine the optimal doses of SKF 38393 for 
inducing oral activity, a dose-response curve was 
constructed (fig. 11). In the saline control group, SKF 
38393 at a dose of 0.1 mg/kg and higher resulted in only a 
slight increase in oral activity. In the 6-OHDA group, the 
threshold dose of SKF 38393 was 0.03 mg/kg, with oral 
activity increasing to 15 ± 2.9 movements (p < 0.01). At 
higher doses of SKF 38393 there were about 40 oral movements 
during the session (p < 0.005).
Effect of combined D1 aoonlat and D1 antagonist treatments
To determine whether a DA D1 receptor antagonist would 
attenuate the oral responses of rats to a D1 agonist, rats 
were treated with sch 23390 (0.3 mg/kg, i.p.) 1 hr before
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SKF 38393 (0.3 mg/kg, i.p.}* As shown in fig. 12, SCH 23390 
attenuated the action of SKF 38393 (p < 0.005), indicating 
that SKF 38393-induced oral activity is a Dl-receptor- 
mediated event.
Dose-responsa study of m-CPP-lnduced oral activity
To determine the optimal dose of m-CPP for induction of 
the oral response, a series of doses of m-CPP was 
administered to rats. As shown in fig. 13, the oral 
response was increased in both the control and 6-0HDA- 
lesioned groups of rats after m-CPP doses in the range of
0.5 to 8.0 mg/kg i.p.. The overall response was greater in
the 6-OHDA vs. the control group of rats (p < 0.001), with 
the apparent maximal response in the 6-OHDA-lesioned rats 
occurring at the 4.0 mg/kg dose of m-CPP.
Effects of S-HT1A and 5-HT,P receptor agonists on oral
activity
To determine the possible involvement of 5-HT( 
receptors on induction of oral activity, rats were treated 
with either the 5-HTtA receptor agonist, 8-OH-DAPT HBr (0.1 
mg/kg s.c., 10 min before observation) or the 5-HT,0 
receptor agonist, CGS-12066B maleate (7-trifluoromethyl-4(4- 
methyl-l-piperazinyl)pyrrolo[l,2-alquinoxaline], 1:2 maleate 
salt, 3.0 mg/kg i.p., 10 min before observation). As shown 
in fig. 14, 8-OH-DPAT did not induce an oral response in
55
rats. Also, CGS-12066B did not produce a statistically 
significant increase in oral activity in control and 6-OHDA- 
lesioned rats (fig. 14}.
Effects of 5-HT receptor antagonists on m-CPP-lnduced oral 
activity
To assess whether m-CPP might produce enhanced oral 
activity through an action on several different types of 5- 
HT receptors, a variety of 5-HT receptor antagonists were 
administered in conjunction with m-CPP (1.0 mg/kg i.p.). 
After pretreatment with mianserin (1.0 mg/kg s.c.), a mixed 
antagonist for 5-HT)c and 5-HT2 receptors, there was complete 
attenuation of the oral response to m-CPP (p < 0.001, fig. 
15). Ketanserin (5.0 rag/kg i.p.), a relatively selective 
antagonist for the 5-HT2 receptor, failed to modify the oral 
response to m-CPP (fig. 15). Similarly, MDL 72222 (10.0 
mg/kg s.c.), a relatively selective antagonist for the 5-HT3 
receptor, failed to alter the response to m-CPP (fig. 15).
Effect of a DA D, receptor antagonist on m-CPP-lnduced oral
To determine whether a DA Dt receptor antagonist would 
attenuate the oral response of rats to the 5-HT agonist, m- 
CPP, rats were treated with SCH 23390 (0.3 mg/kg i.p.). As 
shown in fig. 16, SCH 23390 failed to attenuate the enhanced 
oral response to m-CPP, indicating that 5-HT agonist-induced
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oral activity is not mediated through the DA p! receptor.
Effect of a 5rHTir receptor antagonist on da D,_acrQnlgt^ 
induced oral activity
To determine whether a 5-HTiC receptor antagonist would 
attenuate the oral response to a DA D, receptor agonist, 
rats were treated with mianserin (1.0 mg/kg s.c.) 30 min 
before SKF 38393 (1.0 mg/kg i.p.). As shown in fig. 17, 
pretreatment with mianserin attenuated the enhanced oral 
response to SKF 38393, in both control (p < 0.05) and 6- 
OHDA-lesioned rats (p < 0.001), This finding indicates that 
the oral response of rats to a D( agonist is mediated via a
5-HT system involving 5-HTJC receptors.
Effect of neonatal 6-OHDA treatment on concentrations of_PA^
5-HT and their metabolites in the striatum
As expected, neonatal 6-OHDA treatment profoundly 
reduced striatal DA, HVA and DOPAC contents (>98% reduction, 
p < 0.001; table 5). Accompanying this change was an 
elevation in striatal 5-HT content by 77% (p < 0.001), and a 
slight but not statistically significant increase in 5-HIAA 
content (table 5).
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Effect of neonatal 6-QHPA and ontogenet_ic_8KF_3a393 
treatmentg_on mRNA levels for B-HT^ recaptors of the 
striatum
To evaluate the effect of neonatal 6-OHDA and 
ontogenetic SKF 38393 treatments on 5-HTlc receptor gene 
transcription, dot blot analysis was also employed. There 
was no significant difference in the mRNA levels for 5-HT,c 
receptors in the striatum between neonatal 6-OHDA-lesioned 
and intact rats (fig. ISA). Ontogenetic treatments of 
either intact or lesioned rats with SKF 38393 did not alter 
the mRNA level for the 5-HTlc receptor (fig. 18A). After 
repeated administration of SKF 38393 in adulthood, there 
was still no change in 5-HT(C receptor mRNA in saline, 6- 
OHDA, SKF 38393, and 'SKF 38393 + 6-OHDA' treatment groups 
(fig. 18B).
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TABLE 1
Behavioral effects of acute saline challenge in rats treated 
developmentally with SKF 38393 or saline, in combination with 
single i.c.v. injection of 6-OHDA or its vehicle.
Group
Behavior Saline SKF 38393 6-OHDA 6-OHDA + SKF
Sniffing 49.7 ± 10.7 174.0 ± 50.6 66.8 + 34.3 93.6 ± 25.0
Locomotion 1.5 ± 1.0 5.2 ± 2.6 1.7 ± 0.9 3.0 ± 1.2
Grooming 38.2 ± 12.1 37.4 ± 24.7 21.6 + 7.8 57.6 ± 31.4
Eating 4.2 ± 4.2 26.4 + 16.1 7.5 ± 4.7 10.1 ± 4.8
Taffy pulling 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Digging 1.0 ± 0.4 1.8 ± 1.2 0.8 + 0.4 1.1 ± 0.6
Gnawing 6.5 ± 0.9 7.8 ± 3.1 13.4 + 2.8 15.2 ± 2.6
Paw treading 0.0 ± 0.0 0.0 ± 0.0 0.0 + 0,0 0.0 ± 0.0
Yawning' 0.3 ± 0.3 0.0 ± 0.0 0.6 + 0.3 0.2 ± 0.1
Raring' 5.6 ± 2.3 10.2 ± 3.8 5.3 + 2.9 3.8 ± 1.4
Immobility 493.0 ± 20.7 337.2 :t 64.2 482.3 ± 38.6 414.9 ± 36.2
Behavioral activity was determined in rats that were treated during 
postnatal development with a DA D, agonist, SKF 38393 HCl (3.0 mg/kg 
per day x 28 days, i.p., from day of birth and/or the catecholamine 
neurotoxin 6-OHDA HBr (200 /ig i.c.v., salt form, at 3 days from 
birth; desipramine pretreatment, 1 hr). Rats were challenged with 
saline at 8 weeks from birth and were immediately observed for 
stereotyped behaviors for 10 min. Behaviors were thus quantified 
as seconds in which each individual behavior was performed by a 
rat. The total observation time was 600 seconds. lYawning and 
rearing behaviors were counted as numbers of incidents, not 
seconds. Each group is the mean of 10 rats.
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TABLE 2
Behavioral effects of acute SKF 38393 in rats treated 
developmentally with SKF 38393 or saline, in combination with 
single i.c.v. injection of 6-OHDA or its vehicle.
Group
Behavior Saline SKF 38393 6-OHDA 6-OHDA + SKF
Sniffing 49.5 ± 14.2 95.2 ± 24.0 22.8 ± 7.6 54.8 ± 34.6
Locomotion 1.8 ± 0.9 0.8 ± 0.5 351.7 ± 59.6* 228.9 ± 74.8*
Grooming 135.4 ± 21.8 95.6 ± 22.0 4.3 + 4.3* 3.5 ± 3.5*
Eating 0.5 ± 0.5 1.8 ± 1.0 0.0 ± 0.0 0.0 ± 0.0
Taffy pulling 0.0 ± 0.0 0.0 ± 0.0 0.0 i 0.0 172.5 ± 87.8*+
Digging 0.4 ± 0.3 2.1 + 1.2 2.3 ± 1.9 0.0 ± 0.0
Gnawing 12.1 ± 2.3 7.7 ± 1.8 1.1 ± 0.7* 0.0 + 0.0*
Paw treading 0.0 ± 0.0 0.0 ± 0.0 89.0 ± 50.2* 140.3 ± 75.8*
Yawning* 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Raring* 4.1 ± 1.8 4.3 ± 1.7 7.2 + 2.9 13.3 ± 5.5
Immobility 396.1 ± 34.4 392.5 ± 38.0 84.1 ± 56.3* 0.0 ± 0.0*+
Behavioral activity was determined in rats that were treated during 
postnatal development with a DA D, agonist, SKF 38393 HCl (3.0 mg/kg 
per day x 28 days, i.p., from day of birth) and/or the 
catecholamine neurotoxin 6-OHDA HBr (200 nq i.c.v., salt form, at 
3 days from birth; desipramine pretreatment, 1 hr). Rats were 
challenged with SKF 38393 HCl (3.0 mg/kg i.p.) at 8 weeks from 
birth and were immediately observed for stereotyped behaviors for 
10 min. Behaviors were thus quantified as described in Table 1 
legend. Each group is the mean of 10 rats.
*p < 0.000 vs. saline control group; +p < 0.01 vs. 6-OHDA group.
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TABLE 3
Effect of neonatal 6-OHDA and ontogenetic SKF 38393 treatments on 
concentrations of DA, 5-HT and their metabolites in the striatum 
of adult rats.
MONOAMINES (nmol/g)
GROUP n DA HVA DOPAC 5-HT 5-HIAA
Saline 6 79.2±2.3 8.6±0,5 16.110.4 4.010.1 5.210.2
SKF 38393 5 74.1±3.0 8.210.3 13.810.6 3.910.2 5.210.3
6-OHDA 10 0.6+0.07* 0.110.03* 0.110.02* 6.810.2* 7.010.3*
SKF 38393
+
6-OHDA
9 0.6±0.08* 0.210.05* 0.210.08* 6.210.2* 6,810.2*
Rats were treated daily with vehicle or SKF 38393 HCl (3.0 mg/kg 
i.p.) for 28 consecutive days from birth in combination with 
i.c.v. injection of 6-OHDA (200 jxg, salt form, 3 days after 
birth; desipramine pretreatment, l hr) or its vehicle. Striata 
were removed for assay at 11 weeks. Values are mean nanomoles 
per gram of tissue ± S.E.M.
*p < 0.001 when compared to control group.
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TABLE 4
Computer-modeled parameters for dopamine inhibition of [3H)SCH 23390 
binding in the striatal homogenates of saline, 6-OHDA, SKF 38393 
and 'SKF 38393 + 6-OHDA' treatment groups of rats.
Group % RH Kh (nM) Kl (/iM)
Saline 75.1 ± 2.6 212.2 ± 26.8 30.9 ± 9.9
SKF38393 75.3 ± 3.2 231.6 ± 26.6 29.2 ± 6.8
6-OHDA 68.7 ± 2.6 272.5 ± 38.5 24.4 ± 4.0
SKF38393
+
6-OHDA
73.2 ± 2.0 275.0 ±59.2 30.5 ± 6.8
Rats were treated daily with vehicle or SKF 38393 HCl (3.0 mg/kg 
i.p.) for 28 consecutive days from birth in combination with i.c.v. 
injection of 6-OHDA HBr (200 /ig, salt form, 3 days after birth; 
desipramine pretreatment, 1 hr) or its vehicle. Striata were 
removed for assay at 11 weeks. Competition curves were constructed 
by using 14 concentrations of inhibitor, DA, to compete for 0.45 nM 
[ HJSCH 23390 binding in rat striatum and were fit best by a two- 
site computer derived model where the affinity of [3H]SCH 23390 was 
constrained to be equal (Kd » 0.61 nM) at both high (RH) and low 
(RL) affinity sites. The dissociation constants for high (KH) and 
low (Kt) affinity agonist-binding sites were thus determined by 
using computer program (GraphPad Software Inc., San Diego, CA). 
Data are expressed as mean values or percent ± S.E.M. of 
8 determinations in each treatment group.
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TABLE 5
Effect of neonatal 6-OHDA treatment on concentrations of DA, 5-HT 
and their metabolites In the striatum of rats
Honoamine Treatment % of Control
or Metabolite Saline (n=6) 6-OHDA (n=9)
DA 67.83 ± 1.80 0.95 ± 0.16* 1.4
HVA 7.50 ± 0.53 0.14 ± 0.04* 1.9
DOPAC 14.45 ± 0.87 0.27 ± 0.05* 1.9
5-HT 3.52 ± 0.15 6.23 ± 0.55* 177
5-HIAA 6.53 ± 0.30 7.50 ± 0.60 115
Rats were treated at 3 days after birth with 6-OHDA HBr (200 pg,
l.c.v. salt form; deslpramine pretreatment, 1 hr) or Its vehicle. 
Striata were removed for assay at 9 months. Values are mean 
nanomoles per gram of tissue 1 S.E.M. Numbers In parentheses are 
numbers of samples per group.
*p < 0.001 when compared to vehicle control group.
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EFFECT OF SKF-38393 ON LOCOMOTOR ACTIVITY IN RATS
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Figure 1. Effect of first acute weekly SKF 38393 HC1 (3.0 
mg/kg i.p.) injection on locomotor activity in rats. Rats 
were treated during postnatal ontogeny with either saline 
O f  SKF 38393 Hcl (3,0 mg/kg i.p, daily x 28 days;0H|), 
6-OHDA HBr (200 jig i.c.v., 3 days after birth; desipramine 
pretreatment, 1 hr;H) or combined SKF 38393 + 6-OHDA 
treatments (|). Rats were challenged at 6 weeks from birth 
with SKF 38393 HCl (3,0 mg/kg i.p.), 10 min before 
observation, and then were videotaped for their locomotor 
response for 60 min. Locomotor activity represents the 
distance (meters) traveled by each rat. Each bar indicates 
the mean of 7 to 10 rats. * p < 0.05, vs. control group 
challenged with SKF 38393 HC1; + p < 0.05, vs. same group 
challenged with saline.
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EFFECT OF SKF-38393 ON LOCOMOTOR ACTIVITY IN RATS
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Figure 2. Effect of second acute weekly SKF 38393 HCl (3.0 
mg/kg i.p.) injection on locomotor activity in rats. Rats 
were treated during postnatal ontogeny with either saline 
(□)/ SKF 38393 HC1 (3.0 mg/kg i.p.) daily x 28 days; QQ),
6-OHDA HBr (200 pg i.c.v., 3 days after birth; desipramine 
pretreatment 1 hr;g) or combined SKF 38393 + 6-OHDA 
treatments (»• Rats were challenged at 7 weeks from birth 
with SKF 38393 HCl (3.0 mg/kg i.p.), 10 min before 
observation, and then were videotaped for their locomotor 
response for 60 min. Locomotor activity represents the 
distance (meters) traveled by each rat. Each bar indicates 
the mean of 7 to 10 rats. * p < 0.05, vs. control group 
challenged with SKF 38393 HC1; + P < 0.05, vs. same group 
challenged with saline.
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EFFECT OF SKF-38393 ON LOCOMOTOR ACTIVITY IN RATS
1000
*+
gOOh Fourth Injection
600 
400 
200
0
Acute Saline 
Treatment
Acute SKF 38393 
Treatment
Figure 3. Effect of fourth acute weekly SKF 38393 HC1 (3.0 
mg/kg i.p.) injection on locomotor activity in rats. Rats 
were treated during postnatal ontogeny with either saline 
O ,  SKF 38393 HC1 (3.0 mg/kg i.p. daily x 28 days; Dffl) ,
6-OHDA HBr (200 jig i.c.v., 3 days after birth; desipramine 
pretreatment, 1 hr; H) or combined SKF 38393 + 6-OHDA 
treatments (■). Rats were challenged at 9 weeks from birth 
with SKF 38393 Hcl (3.0 mg/kg i.p.), 10 min before 
observation, and then were videotaped for their locomotor 
response for 60 min. Locomotor activity represents the 
distance (meters) traveled by each rat. Each bar indicates 
the mean of 7 to 10 rats. * p < 0.05, vs. control group 
challenged with SKF 38393 HC1; + p < 0.05, vs. same group 
challenged with saline.
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DOPAMINE INHIBITION OF [3H]SCH 23390 BINDING
IN RAT STRIATUM
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Figure 4. Competition of DA for 0.45 nM [3H]SCH 23390 
binding in the striatum of the saline group of rats. Rats 
were treated with vehicle i.c.v. injection (bilateral; 
desipramine pretreatment; 3 days after birth) and the 
striata were removed 11 weeks from birth. The competition 
curve in striatal homogenates was fit best by a two-site 
computer derived model where the affinity of (JH]SCH 23390 
was constrained to be 0.61 nM. Each data point represents 
the mean of 8 determinations + S.E.M.. The competition curve 
was analyzed as in table 4.
67
CD 
2 : 1—1 
□  
2  
I—I
CO
_J
-<
I—
□
€
■H
X
(0
e
o
a-s
DOPAMINE INHIBITION OF [3H]SCH 23390 BINDING
IN RAT STRIATUM
120
SKF 38393100
80
60
40
20
0
4 -3 -26 58 79
log [DOPAMINE] (M)
Figure 5. Competition of DA for 0.45 nM [JH]SCH 23390 
binding in the striatum of the ontogenetic SKF 38393 group 
of rats. Rats were treated ontogenetically with SKF 38393 
HC1 (3.0 mg/kg i.p. daily x 28), the striata were removed at 
11 weeks from birth. The competition curve was constructed 
as in figure 4.
DOPAMINE INHIBITION OF [3H]SCH 23390 BINDING
IN RAT STRIATUM
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Figure 6. Competition of DA for 0.45 nM (3H]SCH 23390 
binding in the striatum of the neonatal 6-OHDA group of 
rats. Rats were treated neonatally with 6-OHDA HBr (200 jig
i.c.v., 3 days after birth; desipramine pretreatment), and 
the striata were removed at 11 weeks from birth. The 
competition curve was constructed as in figure 4.
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Figure 7. Competition of DA for 0.45 nM [JH)SCH 23390 
binding in the striatum of the neonatal 6-OHDA plus 
ontogenetic SKF 38393 group of rats. Rats were treated
ontogenetically with SKF 38393 HC1(3.0 mg/kg i.p. daily x
28) and lesioned neonatally with 6-OHDA HBr (200 /ig i.c.v., 
3 days after birth; desipramine pretreatment). The striata 
were removed at 11 weeks from birth. The competition curve
was constructed as in figure 4.
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STRIATAL DOPAMINE D1 RECEPTOR mRNA LEVELS 
BEFORE TREATMENTS WITH SKF 38393 IN ADULT RATS
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Figure 8A. Effects of neonatal 6-OHDA and ontogenetic SKF 
38393 treatments on striatal mRNA levels for DA D, receptors 
before treatments with SKF 38393 in adulthood. Each bar 
represents the mean (± s.E.M.) ratio of optical density for 
D, receptor mRNA vs. that for ft-actin mRNA. * p < 0.05 vs. 
saline group.
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STRIATAL DOPAMINE Dl RECEPTOR mRNA LEVELS 
AFTER TREATMENTS WITH SKF 38393 IN ADULT RATS 
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Figure 8B. Effects of neonatal 6-OHDA and ontogenetic SKF 
38393 treatments on striatal mRNA levels for DA D, receptors 
after treatments with SKF 38393 in adulthood. Each bar 
represents the mean (± S.E.M.) ratio of optical density for 
D, receptor mRNA vs. that for fl-actin mRNA. No significant 
differences were observed among saline, SKF 38393, 6-OHDA 
and 'SKF 38393 + 6-OHDA' treatment groups.
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DOPAMINE-STIMULATED STRIATAL ADENYLATE CYCLASE 
ACTIVITY IN RATS
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Figure 9. Effects of neonatal 6-OHDA and ontogenetic 
SKF 38393 treatments on DA-stimulated adenylate cyclase 
activity. Each point represents the mean (± S.E.M.) cAMP 
production (pmoles/mg protein/min) of 5 to 6 determinations. 
The basal enzyme activities for saline, SKF 38393, 6-OHDA 
and SKF 38393 + 6-OHDA treatment groups are: 19.0 ± 2.7,
19.1 ±3.6, 14.7+2.3, and 19.6 ± 2.1 pmoles/mg 
protein/min, respectively. No significant differences in 
stimulation were observed between the treatment groups.
* p < 0.05, vs. basal activity in the same group.
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STRIATAL BASAL, NaF- OR FORSKOLIN-STIMULATED 
ADENYLATE CYCLASE ACTIVITY IN ADULT RATS
° Saline
BASAL
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■ SKF 38393 
+ 6-OHDA
FORSKOLIN
Figure 10. Effects of neonatal 6-OHDA and ontogenetic
SKF 38393 treatments on basal adenylate cyclase activity and
NaF- and forskolin-stimulated adenylate cyclase activity.
No significant differences were observed among saline,
SKF 38393, 6-OHDA and 'SKF 38393 + 6-OHDA' treatment groups 
on basal enzyme activity. NaF and forskolin increased 
adenylate cyslase activity in all treatment groups, but the 
relative increase was not statistically significant among 
these four groups of rats.
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SKF 38393-INDUCED ORAL ACTIVITY IN RATS
□ Control
6-OHDA
0.0 0.03 0.1 0.3 1.0 3.0
Dose of SKF 38393 (mg/kg)
Figure IX. Dose-response relationship for SKF 38393-induced 
oral activity in rats. Numbers of oral movements were 
determined for one minute every 10 minutes over a 60-min 
period, starting 10 minutes after SKF 38393 HC1 (0.03 to 
3.0 mg/kg i.p.). Each group is the mean of 4 to 6 rats.
The number of oral movements in 6-OHDA vs. control rats is 
different at each respective dose of SKF 38393 (p < 0.01).
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ATTENUATION OF SKF 38393-INDUCED ORAL ACTIVITY
IN RATS BY SCH 23390
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SCH 23390
Figure 12. Attenuation of SKF 38393-induced oral activity in 
rats by SCH 23390. Numbers of oral movements were 
determined for one minute every 10 minutes, for 60 minutes, 
starting 10 minutes after SKF 38393 HC1 (0.3 mg/kg i.p.) and 
60 minutes after SCH 23 390 HCl (0.3 mg/kg i.p.). Each group 
is the mean of 4 to 6 rats. * p < 0.005 vs. other 6-OHDA 
groups.
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m-CPP-INDUCED ORAL ACTIVITY IN RATS
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Figure 13. Dose-response relationship for m-CPP-induced oral 
activity in control and 6-OHDA-lesioned rats. Rats were 
studied for oral activity as in figure 11. Each bar 
represents mean number of oral movements ± S.E.M.. Each 
m-CPP dose produced a greater response in the 6-OHDA vs. 
control group. * p < 0.01; ** p < o.ooi vs. respective 
control or 6-OHDA group challenged with saline.
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EFFECTS OF SEROTONIN IA AND IB RECEPTOR AGONISTS 
ON ORAL ACTIVITY IN RATS
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Figure 14. Effects of 8-OH-DPAT, a 5-HT,A receptor agonist, 
and CGS-12066B, a 5-HTin receptor agonist, on oral activity 
in control and 6-OHDA-lesioned rats. Rats were observed for 
oral activity, as described in figure 11. The number of 
oral movements was determined in the l-hr interval, starting 
10 min after challenge treatment with saline, or 8-OH-DPAT 
(0.1 mg/kg s.c.}, or CGS-12066B (3.0 mg/kg i.p.). Each 
group is the mean of 8 to 9 (control) or 11 to 14 (6-OHDA 
lesioned) rats. There was no statistically significant 
increase in oral activity after 8-OH-DPAT or CGS-12066B 
treatments.
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EFFECTS OF SEROTONIN RECEPTOR ANTAGONISTS 
ON m-CPP-INDUCED ORAL ACTIVITY IN RATS
80 r
□  Control
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Figure 15. Effects of 5-HT receptor antagonists on m-CPP- 
induced oral activity in control and 6-OHDA-lesioned rats. 
Rats were studied for oral activity as in figure 11. 
Mianserin HC1 (1.0 mg/kg s.c.), ketanserin tartrate 
(5.0 mg/kg i.p.) and MDL 72222 (10.0 mg/kg i.p.) were 
administered 30 min before m-CPP 2HC1 (1.0 mg/kg i.p.) or 
its vehicle. Each group is the mean (± S.E.M.) of 6 to 11 
rats. * p < 0.001 vs. m-CPP effect in the 6-OHDA-lesioned 
rats.
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LACK OF EFFECT OF SCH 23390 
ON m-CPP-INDUCED ORAL ACTIVITY IN RATS
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Figure 16. Lack of effect of SCH 23390 on m-CPP-induced oral 
activity in control and 6-OHDA-lesioned rats. Rats were 
studied for oral activity as in figure 11. SCH 23390 
(0.3 mg/kg i.p.) was administered 1 hr before m-CPP 2HC1 
(1.0 mg/kg i.p.) or its vehicle. Each group is the mean 
(± S.E.M.) of 4 to 11 rats. SCH 23390 did not attenuate the 
effect of m-CPP (p > 0.05).
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ATTENUATION OF SKF 38393-INDUCED ORAL ACTIVITY
IN RATS BY MIANSERIN
45
40 
35 
30 
25 
20 
15 \r 
10 
5 
0
□  Control 
■  6-OHDA Lesioned
f t
Saline Mianserin SKF 38393 Mianserin +
SKF 38393
Figure 17. Attenuation of SKF 38393-induced oral activity in 
control and 6-OHDA-lesioned rats by mianserin. Rats were 
studied for oral activity as figure 11. Mianserin HC1 (1.0 
mg/kg s.c.) was administered 30 min before SKF 38393 HC1 
(1.0 mg/kg i.p.) or its vehicle. Each group is the mean 
(± S.E.M.) of 4 to 11 rats. * p < o.ooi vs. other groups.
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STRIATAL SEROTONIN 1C RECEPTOR mRNA LEVELS 
BEFORE TREATMENTS WITH SKF 38393 IN AOULT RATS
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Figure 18A. Effects of neonatal 6-OHDA and ontogenetic 
SKF 38393 treatments on striatal mRNA levels for 5-HTlc 
receptors before treatments with SKF 38393 in adulthood.
Each bar represents the mean (± S.E.M.) ratio of optical 
density for 5-HTir receptor mRNA vs. that for 0-actin mRNA. 
No significant differences were observed among saline,
SKF 38393, 6-OHDA and 'SKF 38393 + 6-OHDA' treatment groups.
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STRIATAL SEROTONIN IC RECEPTOR mRNA LEVELS 
AFTER TREATMENTS WITH SKF 38393 IN ADULT RATS
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Figure 18B. Effects of neonatal 6-OHDA and ontogenetic 
SKF 38393 treatments on striatal mRNA levels for 5-HTIC 
receptors after treatments with SKF 38393 in adulthood.
Each bar represents the mean (± S.E.M.) ratio of optical 
density for 5-HTlt: receptor mRNA vs. that for B-actin mRNA. 
No significant differences were observed among saline,
SKF 38393, 6-OHDA and 'SKF 38393 + 6-OHDA' treatment groups.
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Chapter 4 
Discussion
DR D. Receptor supersensitization
Neonatal treatment of rats with a catecholamine 
neurotoxin, 6-OHDA, results in the supersentization of DA 
receptors. That is, doses of L-dihydroxyphenylalanine (L~ 
DOPA), apomorphine or SKF 38393 which have little effect in 
intact rats, produce marked changes in stereotyped and 
locomotor behaviors in the lesioned rats that were tested as 
adults (Breese et al., 1984, 1985a,b, 1987; Hamdi and 
Kostrzewa, 1991). The DA Di receptor antagonist, SCH 23390, 
attenuates the enhanced stereotyped and locomotor behaviors 
by the D: agonist, SKF 38393, in the lesioned rats, 
indicating that Dx receptors are specifically involved in 
the induced receptor sensitization (Breese et al., 1985a,b, 
1987). The ability to sensitize D: receptors appears to be 
related to immaturity of the DA system at the time of 
lesioning, since 6-OHDA treatment of adult rats is not 
associated with such receptor sensitization (Breese et al., 
1984). Actually, a latent supersensitization of Dt 
receptors occurs with this lesion, and the sensitization 
process is only unmasked by repeated DA D: agonist 
treatments in adulthood (Criswell et al., 1989, 1990;
Johnson et al., 1992). This process of induction of long- 
lived Dj receptor supersensitivity is known as ' priming'
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(Breese et al., 1985b; Criswell et al., 1989). Recently, 
Hamdi and Kostrzewa (1991) reported that the D, receptors 
could be ontogenetically sensitized by repeated Dt agonist 
treatments during the first 33 days after birth. As in 
adult-primed rats, there was an enhancement of the D, 
agonist-induced stereotyped behaviors in adulthood. Also, 
as in studies by Breese and co-workers, there was no change 
in the B,^ or Kj for D, binding in the striatum of these rats 
(Breese et al., 1987).
The status of the DA Dt receptor during postnatal 
ontogeny is not completely resolved. There are some reports 
of only slight change in the B ^  and Kd for []H]SCH 23390 
binding to striatal homogenates in the first 1 to 2 months 
after birth (Broaddus and Bennett, 1990), and other reports 
of a dramatic increase in B„„ during the first 4 to 5 weeks 
after birth (Giorgi et al., 1987; Zeng et al., 1988) and 
even transient increases in the Kd in this interval (Zeng et 
al., 1988). Using histochemical methods, however, it has 
been clearly demonstrated that DA D, receptors develop in 
patches in the striatum, being closely associated with DA 
nerve terminal input to these patches (Zeng et al., 1988).
As D, receptors increase in number, the striosomal pattern 
of DA D, receptors becomes obscured by the global increase 
in DA D| receptors in the matrix of the striatum. This 
pattern of DA D, receptor development indicates that the 
early series of SKF 38393 treatments in the present study
would initially interact only with the population of DA D, 
receptors that had developed up to that point in tine. 
Interaction of SKF 38393 with striatal DA D, receptors would 
change during development, as the population of the receptor 
continued to increase in number during ontogeny. In theory, 
each subsequent dose of SKF 38393 was able to act at greater 
numbers of Dt receptors, which would mean that there was 
unequal exposure of the DA D, receptor population to the DA 
D, agonist. Perhaps this relates to the inability of SKF 
38393 to fully sensitize DA D, receptors to later SKF 38393- 
induced locomotor activity effects.
Although many SKF 38393-induced responses of neonatal- 
sensitized and adult-primed rats are similar, there are some 
differences in degree of response for many behaviors, which 
possibly are related to the extent of sensitization. The 
extent of DA D, sensitization in those rats treated 
repeatedly in postnatal ontogeny with the DA D, agonist, SKF 
38393 was investigated in the present study. For that 
reason the locomotor responses to SKF 38393 were determined 
after the first 2 doses and after the last dose of the D( 
agonist. It is clear from effects observed in rats treated 
only with neonatal 6-OHDA, that adult priming was essential 
for unmasking of the latent supersensitivity of D, 
receptors. In essence, the first dose of SKF 38393 produced 
only a slight increase in the locomotor response of rats, 
while subsequent doses produced increasingly greater effects
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(7th bars of figs. 1-3; p < 0.05, ANOVA). This finding in 
the present study is in full agreement with those earlier 
reports (Breese et al., 1985b; Criswell et al., 1989, 1990).
In contrast to this effect, sensitization of DA Dt 
receptors was evident with the first challenge dose of SKF 
38393 at 6 weeks, in neonatal 6-OHDA lesioned rats that were 
treated daily with SKF 38393 during the first 4 weeks of 
postnatal ontogeny. That is, an enhanced locomotor response 
was observed after initial SKF 38393 treatment in adulthood 
(8th bar of fig, l, p < 0.05). Subsequent SKF 38393 
challenge doses increased locomotor activity to a level 
ultimately about 3-fold greater than that seen after the 
first adult challenge dose (8th bars of figs. 2-3). 
Therefore, it appears that ontogenetic treatments of 
neonatal 6-OHDA-lesioned rats with SKF 38393 produces 
partial but not complete DA D, receptor supersensitization. 
Additional adult SKF 38393 treatments were necessary to 
produce the maximal level of D, sensitivity.
Because locomotor activity is only one of several kinds 
of behaviors induced by DA agonists, we observed rats for 
SKF 38393-induced stereotypies at 8 weeks. DA Dt agonists 
produce exaggerated stereotyped behavioral responses in 
neonatal 6-OHDA-lesioned rats (Breese et al., 1984, 1985a,b, 
1987; Hamdi and Kostrzewa, 1991). It was important to 
determine if several SKF 38393 challenge treatments would 
substantially modify the stereotypy effect of a DA Dt
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agonist in adult rats. We found that ontogenetic SKF 38393 
treatments did not markedly influence stereotyped responses 
in neonatal 6-OHDA-lesioned rats. Virtually all of the 
behaviors were expressed in both the 6-OHDA group and 'SKF 
38393 + 6-OHDA' group, except for taffy pulling, which was 
expressed in only the latter group. Also, immobility time 
was less in this group vs. the 6-OHDA group. These findings 
suggest that ontogenetic SKF 38393 treatments are able to 
partially modify later stereotyped behavioral effects of a 
DA D| agonist.
Despite the fact that a different method was used in 
the present study to evaluate stereotyped behavior, 
virtually all of the SKF 38393-induced responses are similar 
to those observed previously in rats that were lesioned 
neonatally with 6-OHDA and ontogenetically sensitized with 
SKF 38393 (Hamdi and Kostrzewa, 1991}. The one exception is 
that SKF 38393-induced grooming is reduced in the present 
study, compared to an enhanced grooming response in the 
previous study (Hamdi and Kostrzewa, 1991). This difference 
may relate to additional priming in adulthood in the present 
study. It is likely that, as D(-related behaviors became 
more prominent with additional SKF 38393 treatments in 
adulthood, the competing behaviors resulted in less grooming 
behavior. In essence, a rat can only exhibit so many 
behaviors at one time, so an increase in performing of one 
behavior might be expected to diminish the time spent in
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another behavior.
Given the behavioral aberrations observed in both 
neonatal 6-OHDA-lesioned rats and those receiving combined 
neonatal 6-OHDA and ontogenetic SKF 38393 treatments in the 
present study, a DA competition for [3H]SCH 23390 binding 
analysis was performed from striatal homogenates of the 
rats. This was done because earlier reports showed a lack 
of change of D, receptor number and affinity by either using 
striatal homogenates (Breese et al., 1987; Duncan et al., 
1987; Dewar et al., 1990; Hamdi and Kostrzewa, 1991) or 
performing autoradiography (Luthman et al., 1990; Simson et 
al., 1992), after neonatal 6-OHDA treatment. As yet, very 
little is known about whether numbers of high affinity D, 
receptor would be altered in these rats or in rats given 
both neonatal 6-OHDA and ontogenetic D, agonist treatments. 
No change in high affinity binding sites for DA D, receptors 
was noted in neonatal 6-OHDA vs. saline rats when using DA 
competition for radiolabeled D, antagonist binding (table 
4). Also, in the present study postnatal treatment of 
neonatal 6-OHDA-lesioned rats with SKF 38393 did not affect 
the distribution of high and low affinity agonist binding 
sites (table 4). Collectively, these results demonstrate 
that behavioral supersensitivity to systemic administration 
of DA D| agonist in adulthood, or priming of rats lesioned 
as neonates and those given neonatal lesion plus ontogenetic 
treatment with the D, agonist, is neither due to increased D,
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receptor number in general, nor is it due to altered high 
affinity receptor binding in particular.
With the techniques of recombinant DNA technology being 
used, specific sequences encoding different types of DA 
receptor including rat (Zhou et al., 1990) and human D, 
receptors (Dearry et al., 1990; Sunahara et al., 1991), have 
been cloned .and sequenced, and thereby can be used to 
analyze the receptor gene expression in the brain.
Therefore, availability of the receptor mRNA probe has made 
it possible to analyze the specific mRNA coding for DA D( 
receptor and thus to have a better understanding of the 
receptor regulation and supersensitivity after neonatal 6- 
OHDA lesion. In order to investigate whether the enhanced 
locomotor and stereotyped responsiveness of the lesioned 
rats to adult challenge doses of D, agonist is attributable 
to an altered rate of transcription of the gene or the mRNA 
for DA D, receptors, we also evaluated the effect of SKF 
38393 treatments on expression of the gene coding D, 
receptors. The finding that the level of D, receptor mRNA 
after neonatal 6-OHDA was reduced, regardless of whether 
ontogenetic SKF 38393 was co-administered, suggests that 6- 
OHDA chemical lesion influences the receptor gene 
expression. Gelbard et al. (1990) demonstrated that 
neonatal development of DA D, receptors in rat forebrain was 
impaired after 6-OHDA lesion. These investigators suggested 
that in the absence of endogenous DA, the Dt receptors may
possibly either fail to develop adequately or fail to be 
maintained. The present data reveal possible molecular 
mechanisms underlying this biochemical event. Our finding 
indicates that neonatal 6-OHDA lesion impairs ontogeny of DA 
Dj receptors due to failure of receptor gene expression. 
After repeated treatments with SKF 38393 in adulthood (adult 
priming), there was no change in striatal Dt mRNA levels 
among the treatment groups, indicating that priming restores 
D, receptor gene expression in the lesioned rats. These 
results are in accord with previous studies, demonstrating 
that priming of striatal D, receptors in neonatal 6-OHDA 
lesioned rats occurred in the absence of altered D, receptor 
density and affinity (Breese et al., 1987; Duncan et al., 
1987; Dewar et al., 1990; Luthman et al., 1990; Hamdi and 
Kostrzewa, 1991). Moreover, these findings are fully 
consistant with the above agonist competition for 
radiolabeled DA D, antagonist binding data, indicating that 
the DA D| receptor recognition site after neonatal 6-OHDA 
lesion may not be a critical factor in the development of 
behavioral supersensitivity to DA D, agonist.
Based on pharmacological manipulation of adult animals, 
it has been proposed that alterations in DA D, receptor mRNA 
by repeated reserpine treatments (Butkerait and Friedman, 
1993) or by chronic DA D, receptor blockade (Schettini et 
al., 1992) are associated with an increased level of mRNA 
coding for G protein alpha subunit (Nsa). The present data
showed that after adult priming with a D, agonist, the level 
of Dt receptor mRNA in neonatally lesioned or combined 
neonatally lesioned plus ontogenetically sensitized rats did 
not differ from that of the control at a time when 
behavioral sensitization of the animals is known to occur. 
Taken together, these studies suggest that a site distal to 
the DA D| receptor recognition site, or possibly, a site 
rather than in DA neurochemical system but in a system or 
systems modulating DA-mediated effects, accounts for the 
apparent supersensitization of D, receptor-related function.
The present study, using DA to stimulate adenylate 
cyclase in the presence of spiperone, indicates that the 
link of DA D, receptors to this enzyme is not changed in the 
striatum by lesioning neonates with 6-OHDA, in spite of 
profound depletion of striatal DA content and 
supersensitized behavioral responses. Moreover, we found 
that forskolin- and NaF-stimulated adenylate cyclase 
activity did not differ in lesioned and intact rats. 
Additionally, ontogenetic treatments with SKF 38393 failed 
to affect basal and DA-stimulated adenylate cyclase activity 
in both neonatal lesioned and intact animals. This finding 
supports that of Sirason et al. (1992), who found that 
agonist-stimulated adenylate cyclase activity did not change 
in neonatal 6-OHDA lesioned rats that were primed in 
adulthood. It appears that DA Dt receptor linked adenylate 
cyclase is also not a major determinant of supersensitized
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behavioral responses to D( agonists in neonatal 6-OHDA- 
lesioned rats.
It is well established that neonatal 6-OHDA treatment 
of rats is associated with a marked reduction in the
t
striatal level of DA, due to destruction of nigrostriatal 
neurons (Breese and Traylor, 1971, 1972; Breese et al., 
1984), and an elevation in 5-HT content (Breese et al.,
1984; Stachowiak et al., 1984), due to sprouting and ensuing 
hyperinnervation by 5-HT-containing fibers (Stachowiak et 
al., 1984; Berger et al., 1985; Luthman et al., 1987; Towle 
et al., 1989). The findings in this study are in full 
agreement with those earlier reports. That is, DA content 
of the striatum in 6-OHDA-lesioned rats is profoundly 
reduced by nearly 99%, and DOPAC and HVA contents are 
reduced by a similar amount (table 3). Accompanying these 
changes is the elevation of striatal 5-HT content by 70%, 
and 5-HIAA by 35% (table 3). Additionally, ontogenetic 
treatments of rats with SKF 38393 in the present study, did 
not produce an effect on striatal DA, 5-HT and their 
metabolites, nor did this treatment modify the effect of 6- 
OHDA (table 3). Based on above striatal contents of DA, 5- 
HT and their metabolites found in this study, we feel that 
the animal models are similar to those in earlier studies.
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Mediation of DR Agonist-Induced oral Behavior bv the 5-HT 
System
In neonatal 6-OHDA-lesioned rats a supersensitized 
response to DA D, agonists is observed in adulthood (Breese 
et al., 1985a,b, 1987; Hamdi and Kostrzewa, 1991), despite 
the lack of change in number or affinity of D, receptors 
(Breese et al., 1987; Hamdi and Kostrzewa, 1991). The oral 
activity response to D, receptor agonists and D2 antagonists 
is also enhanced in the neonatal lesioned rats (Kostrzewa 
and Hamdi, 1991). In the present study, the augmented oral 
response to SKF 38393 in lesioned rats is attenuated by SCH 
23390, a DA D, receptor antagonist, indicating that the Dt 
receptor subtype is primarily involved in the enhanced 
response (fig. 12).
Recently, it was found that 5-HT agonists also can 
induce oral activity in rats (Stewart et al., 1989). Since 
the striatal DA depletion in neonatal 6-OHDA-treated rats is 
accompanied by elevated 5-HT levels (Breese et al., 1984; 
Stachowick et al., 1984; Luthman et al., 1987; table 5 in 
the present study) and hyperinnervation of striatum by 5-HT 
fibers (Berger et al., 1985; Snyder et al., 1986), it was of 
interest to determine whether the induction of oral activity 
by 5-HT agonists would be potentiated in these rats. The 
enhanced response to m-CPP over a wide dose range in 
lesioned rats in this study, demonstrates that 5-HT 
receptors are also supersensitized in this group of rats.
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Production of overt supersensitization of 5-HT receptors in 
neonatal 6-OHDA-lesioned rats is suggested by the fact that 
the maximal oral activity response is 2- to 3-fold higher in 
this group vs. control (fig. 13). It has also been shown 
that m-CPP acts directly as a 5-HT agonist that lacks 5-HT 
uptake inhibitor properties (Fuller et al., 1981).
Therefore, the most likely explanation for m-CPP action 
relates to 5-HT receptor supersensitization.
The series of studies with 5-HT receptor agonists and 
antagonists indicate that 5-HTu and 5-HT,B receptors are not 
associated with oral activity. The agonist, 8-OH-DPAT, is 
relatively selective for 5-HT,A receptors (Arvidsson et al., 
1981; Hiddlemiss and Fozard, 1983}, and the dose used in the 
present study is known to produce a response in vivo (Fuller 
and Snoddy, 1987; Stewart et al., 1989). CGS 12066B, a 
selective 5-HT,B receptor agonist with little activity at D, 
sites (Neale et al., 1987), did not induce oral activity. 
Although we have no direct evidence that CGS 12066B acted at 
the 5-HT|B site in the brain, the dose used in this study is 
more than 10-fold greater than that found by others to alter 
the firing of dorsal raphe neurons (Neale et al., 1987).
Ketanserin and MDL 72222, antagonists with high 
affinity for 5-HT2 (Leysen et al., 1981, 1982) and 5-HTj 
(Fozard, 1984) receptors, respectively, were ineffective in 
attenuating the enhanced oral response to m-CPP. The doses 
of ketanserin and MDL 72222 are similar or higher than that
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known to produce antagonism of 5-HT2 and 5-HTj receptors in 
vivo (Fozard, 1984; Awouters et al., 1990; Nash, 1990).
These findings suggest that 5-HT2 and 5-HT3 receptors are not 
involved in the effect of m-CPP. Attenuation of the 
enhanced oral response to m-CPP by mianserin, an antagonist 
with affinity for both 5-HTlc and 5-HT2 receptors, suggests 
that it is the 5-HTlc receptor subtype that becomes 
supersensitized after loss of DA input to the striatum.
It was not practical to use a wide range of doses for 
the different agonists and antagonists in these studies, and 
it is conceivable that a different dose and/or different 
observation time for some of these agents might have 
resulted in an effect on the oral response. However, based 
on findings with 5-HT receptor agonists and antagonists in 
this study, there is an apparent correlation between 5-HT,c 
receptors and the oral responses of rats.
In the present study, the other major finding is the 
lack of effect of SCH 23390 on m-CPP-induced oral activity. 
This indicates that the DA system is not the final pathway 
in the behavioral event. This finding is in agreement with 
our biochemical studies in which there was no alteration in 
DA D, receptor high affinity binding sites, no change in 
basal and DA-stimulated adenylate cyclase activity, and no 
change in Dt receptor mRNA level after priming in adulthood. 
SCH 23390 has a high affinity for the D, receptor, with an 
ICH for [3H]SCH 23390 binding being about 150 times less
than that for [3H)mesulergine binding (Billard et al., 1984; 
Hoyer et al., 1988). The dose of SCH 23390 in this study is 
similar or identical to that used to specifically attenuate 
oral activity responses to a D, agonist (Levin et al., 1989; 
Rosengarten et al., 1986); to attenuate Dj agonist-induced 
behaviors (Breese et al., 1985a,b; Criswell et al., 1989); 
and to attenuate the development of D, receptors (Saleh and 
Kostrzewa, 1988; Kostrzewa and Saleh, 1989).
The effectiveness of mianserin in attenuating the 
enhanced oral response to SKF 38393, suggests that D, 
receptor-mediated oral activity relies on a 5-HT 
neurochemical system for transduction of the response. The 
DA and 5-HT pathways associated with oral activity may 
operate in sequence, with the 5-HT system representing a 
later stage in this circuit. It is also possible, however, 
for these two neurochemical systems to operate in parallel 
but with the 5-HT system exerting greater control. 
Antagonists of the 5-HT system could conceivably attenuate 
D, agonist-induced oral responses in either design. The 
observed oral response may be a consequence of 5-KT fiber 
sprouting and hyperinnervation in rostral striatum. 
Additional studies are needed to resolve these aspects of 
interaction between the DA and 5-HT neurochemical systems.
In other studies on neonatal 6-OHDA-lesioned rats it was 
reported that the sprouted 5-HT fibers did not seem to 
possess an inhibitory control on endogenous 5-HT- and
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acetylcholine-containing neurons (Jackson et al., 1988), and 
that 5-HT innervation did not appear to be responsible for 
supersensitized locomotor and stereotyped responses to a DA 
agonist (Towle et al., 1989). The present findings 
demonstrate that 5-HT neurons can be intricately involved in 
mediation of supersensitized responses to DA agonists.
To study the effects of neonatal 6-OHDA lesion and 
ontogenetic SKF 38393 treatments on gene expression for 5- 
HTIC receptors, the mRNA levels for the receptor subtype 
were also determined in the present study. Unlike DA D, 
receptors, neither neonatal 6-OHDA nor ontogenetic SKF 38393 
treatments affect mRNA coding for the 5-HTlc receptor.
Also, repeated treatments of both intact and lesioned rats 
with SKF 38393 in adulthood did not influence the levels of 
mRNA for 5-HT,c receptors in the striatum. Therefore, the 
biochemical change responsible for the enhanced oral 
response in 6-OHDA-lesioned rats, other than altered gene 
expession for 5-HTlc receptors, is yet to be determined. It 
has been known that 5-HT,c receptors are coupled to the 
breakdown of phosphatidylinositides (Conn and Sanders-Bush,
1986). An increase in inositol trisphosphates (IP3) was 
reported to be related to the supersensitization of 5-HTlc 
receptors generated by chemical denervation (Conn et al.,
1987). It may be that coupling of the receptor with this 
second messenger system could be different in the 
supersensitized 5-HT,c receptors in our neonatal 6-OHDA rat
model. Alternatively, balance and adjustment among striatal 
DA, 5-HT and other neuronal systems after neonatal 6-OHDA 
lesion may be responsible for the supersensitization of 
multiple neural receptor systems (Kostrzewa and Heely,
1993).
The present series of studies helps to identify the 
altered 5-HT receptor responses that occur in those rats 
with greatly increased oral activity after neonatal 
destruction of DA-containing fibers in the brain. This 
animal model should be useful in studying functional 
associations between central dopaminergic and serotonergic 
neurons. Also, the discovery of a 5-HT neurochemical 
component in enhanced oral dyskinetic activity implicates 
another direction that may be taken toward the discovery of 
agents that modulate dyskinetic oral activity in assorted 
human clinical disorders.
Chapter 5 
Summary
The present series of studies has demonstrated the 
following:
1. Ontogenetic treatments of neonatal 6-OHDA-lesioned rats 
with a DA Dt agonist, SKF 38393, can partially sensitize Dj 
receptors in adulthood.
2. Neonatal 6-OHDA chemical lesions impair DA Di receptor 
ontogeny due to failure of gene expression for the receptor, 
while repeated treatments of the lesioned rats with SKF 
38393 in adulthood result in restoration of the mRNA level 
for D! receptors.
3. Changes in DA Dj receptor high affinity binding, Dx 
receptor mRNA levels, and receptor-stimulated adenylate 
cyclase activity, can not account for supersensitized 
behavioral responses in neonatally lesioned rats.
4. The 5-HTlc receptor subtype becomes functionally 
supersensitized after neonatal destruction of DA input to 
the striatum, in the absence of a change in striatal mRNA 
level for this receptor subtype. Moreover, induction of 
oral activity by a DA D! agonist is mediated via a 
serotonergic system.
5. The neonatal 6-OHDA rat model should be useful in 
exploring functional and neurochemical associations between 
central dopaminergic and serotonergic systems.
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